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HIV is most well-known for its negative effects on the immune system and the resulting development of 
AIDS, however it also has severe damaging effects on the central nervous system. Many infected 
individuals exhibit neuropsychological and behavioral dysfunctions which are collectively referred to as 
HIV-associated dementia (HAD). One of the worrying aspects of HAD is the fact that current anti-retroviral 
therapy, while being effective in managing the onslaughts of HIV on the immune system, is less efficient 
in addressing the impact of HIV on the CNS. The HIV-1 regulatory protein, transactivator of transcription 
(Tat), is responsible for the transactivation of viral transcription, and has been identified as a possible 
etiological factor of HAD. Neurotoxicity caused by HIV-1 is an indirect effect since the virus is unable to 
infect neurons directly. We subsequently hypothesized that HIV-1 infects non-neuronal cells in the CNS 
which leads to their activation, resulting in the release of cytokines that are detrimental to neurons. The 
aims of this study was therefore to (i) determine whether Tat activates astrocytes, (ii) establish whether 
astrocytes exposed to Tat result in the release of IL-6 and TNF-α,  and  to  (iii)  assess  whether  these  cytokines  
can induce apoptosis of neuronal cells. Our study has shown that Tat does activate astrocytes and that 
activated astrocytes do indeed release cytokines IL-6 and TNF-α  into   their   growth  medium. Tat treated 
cells release more than double the amount of IL-6 than the control group of untreated astrocytes. We also 
observed that exogenous administration of these cytokines (individually or collectively) to neurons has the 
ability to cause neuronal apoptosis. Interestingly in combination, these cytokines show no cooperative 
effect. Our data also showed that neurons, when exposed to the culture medium of astrocytes that were 
subjected to Tat, exhibit hallmarks of apoptosis similar to that induced by IL-6 and TNF-α. Our findings 
led us to conclude that in individuals with HIV-infection, the virus activates astrocytes possibly via the 
production and release of Tat. This causes the astrocytes to secrete pro-inflammatory cytokines (e.g. TNF-
α  and IL-6) that may induce apoptotic cell death of neurons. This mechanism may explain the development 
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1.1 Introduction  
Acquired immune deficiency syndrome (AIDS) was first observed in 1981 amongst the young homosexual 
men of New York and California (Fauci, 2003). This disease was characterized by a progressive decline in 
cell mediated immunity, mainly the CD4+ T-cells (Lane, 2010). However, soon diverse groups of 
individuals were infected, indicating that the disease was caused by an infectious microorganism (Fauci, 
2003). By 1983, both epidemiological and virological evidence was established showing that human 
immunodeficiency virus (HIV), a member of the retrovirus family, was the causative agent of AIDS (Fauci, 
2003).  
The 2013 fact sheet of the Joint United Nations Program on HIV/AIDS (UNAIDS) 2013, reported that in 
2012 there were 35.3 million people living with HIV, 2.3 million new infections globally, 1.6 million 
deaths from AIDS- related causes and 9.7 million people accessing treatment (Table 1). The UNAIDS 
global and regional statistics show that in 2012, Sub-Saharan Africa had the largest population of  people 
living with HIV (25 million), new HIV infections (1.6 million) and AIDS-related deaths (1.2 million).                
HIV-1 can be divided into 3 different and highly divergent groups : major, outlier and non-major/outlier 
(Bagashev and Sawaya, 2013). Within the major group, there are 9 subtypes/clades, with subtype C 
predominating worldwide (Bagashev and Sawaya, 2013). Globally, clade C HIV-1 accounts for 56% of 
HIV infections as compared to other clades A,B and D-J (Bagashev and Sawaya, 2013; Ranga et al., 2004; 
Siddappa et al., 2006). Clade C has been successful in establishing rapidly growing epidemics in most 
populations of Sub-Saharan Africa, India, China and Brazil (Siddappa et al., 2006). Even though clade C 
causes the most infections compared to the other subtypes, little is understood about their molecular and 
pathogenic properties (Siddappa et al., 2006). Currently the knowledge of HIV-1 pathogenesis is mainly 
obtained from clade B strains, prevalent in the US and Europe (Alaeus, 2000; Siddappa et al., 2006) and 
the relevance of this knowledge to Sub-Saharan African where clade  C is most prevalent, has been 
questioned.  
The human immunodeficiency virus is spherically shaped with an approximate diameter of 120nm (Freed, 
1998). Its diploid genome is encased by a protective protein coat called the capsid. Between the genome 
lies the essential proteins required for the completion of the viral life cycle. These include reverse 
transcriptase (RT), protease, polymerase and integrase (Figure1) (Freed, 1998; Pomerantz and Horn, 2003). 
  
 
Table 1. Global HIV/AIDS statistics as reported by UNAIDS 
The viral envelope (env) protein, encodes for the surface glycoprotein 120 (gp120) as well as the 
transmembrane glycoprotein 41 (gp41) (Figure 1) (Freed, 1998; Tiwari et al., 2012). These proteins 
function mainly in host cell attachment. Group specific antigen (Gag) proteins make up the capsid, matrix 
and nucleocapsid proteins (Freed, 1998). Polymerase (pol) encodes for RT, proteases and integrase, all of 
which have functions in the life cycle (Freed, 1998). The virus also has regulatory proteins, Tat and Rev, 












 2001 2005 2008 2009 2010 2011 2012 
People living with HIV 
in millions 
30 32.5 33.5 34 34.4 34.9 35.3 
New HIV infections 
in millions 
34 2.9 2.6 2.6 2.5 2.5 2.3 
AIDS-related deaths 
in millions 
1.9 2.3 2.1 2.0 1.9 1.8 1.6 
People accessing treatment  in 
millions 
 1.3 4.1 5.3 6.6 8.1 9.7 
Figure 1. A schematic illustration of the HIV virion (Robinson, 2002). 
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1.2 HIV-1 Life Cycle, Pathogenesis and Therapeutic Approaches 
HIV is an obligate parasite relying solely on host cell machinery for its replication and survival (Collins 
and Collins, 2014).  It’s simple structure does not contain any energy producing or biosynthetic machinery 
(Collins and Collins, 2014). HIV initially targets the immune cells and a drop in these cells’ numbers 
renders an HIV-infected patient more susceptible to several other infections compared to an uninfected 
individual (Lane, 2010; Sierra et al., 2005). As the virus persists, many infections manifest due to the 
weakening of the immune system (Lane, 2010). The body is able to control the virus for a period of time 
until the circulating CD4+ count drops below 200 cell/mm3. This markedly reduced amount of immune 
cells results in a poor host immune response towards the virus, allowing ongoing viral replication (Lane, 
2010) and viral persistence (Ross, 2001). 
1) Viral attachment and fusion  
Once the virus enters the body it binds to CD4+ T-cell receptors and co-receptors, CCR5 or CXCR4 on the 
host target cells (these cells include CD4+ T-cells, macrophages or dendritic cells) (Frankel and Young, 
1998). At this stage receptor blockers can be used to inhibit the binding process, however, these drugs are 
not widely available. The virus then fuses to the host cell and penetrates through the host cell membrane 
entering the host cytoplasm (Frankel and Young, 1998). Fusion and entry can be hindered using fusion and 
entry inhibitors. Uncoating allows the virus to expose its genome and virally encoded proteins (Frankel 
and Young, 1998).  
2) Reverse transcription 
The enzyme reverse transcriptase, reverse transcribes the diploid viral RNA into double stranded DNA by 
using one strand of RNA as a template (Sierra et al., 2005). This process can be blocked by reverse 
transcriptase (RT) inhibitors that prevent the lifecycle of the virus from proceeding. A RT inhibitor is 
commonly one of the components of antiretroviral therapy (ART) (Frankel and Young, 1998).  
3) Integration  
Newly transcribed double stranded DNA enters into the host nucleus where integrase nicks the host genome 
for the integration of the newly transcribed DNA (Sierra et al., 2005). The virus integrated into the host is 
called the provirus, which replicates each time the host cell divides. Integration can be restrained by the 





Figure 2. A schematic representation of the HIV-1 life cycle (Sierra et al., 2005). 
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     4, 5) Transcription and Translation 
The pro-viral genome is transcribed into messenger RNA which is translated into viral proteins gag, pol 
and env (Freed, 1998). The immature virus is at this point called a virion. Maturation of the virion occurs 
once essential viral proteins are cleaved by proteases (Frankel and Young, 1998). 
      6) Assembly, Budding and Maturation 
Subsequent to the viral proteins being cleaved by the protease enzyme into smaller, active, structural 
polypeptides, the mature virus buds away from the host cell and is free to infect other cells (Freed, 1998; 
Stevenson, 2003). The maturation and assembly of HIV can be prevented by the use of protease inhibitors, 












The pathogenesis of the virus depends on the viral replication, the reservoirs that support it and the host 
response to the virus (Stevenson, 2003). All retroviruses require a CD4+ receptor for attachment, however 
the co-receptor could either be CCR5 (if virus is M tropic) or CXCR4 (if virus is T tropic) found on 
macrophages and primary T-cell lines respectively (Stevenson, 2003). The virus is unable to infect cells 
that do not have a CD4+ receptor (Stevenson, 2003). Cells possessing CD4+ receptors include macrophages, 
T lymphocytes and glial cells (Pomerantz and Horn, 2003). Once the virus has infected the surveillance 
cells, the infection migrates to the lymph nodes where there is a burst of viral replication causing extreme 
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viremia (Stevenson, 2003). At this stage of the infection the CD4+ and CD8+ T lymphocytes are activated 
keeping the viral load low (Stevenson, 2003). However, as the CD4+ cell count continues to drop the body’s 
immune response becomes too weak to control the virus (Stevenson, 2003).  
Clinically an HIV-infected person displays flu-like symptoms (Sierra et al., 2005; Stevenson, 2003). 
During this initial stage the body’s HIV-1 specific immune response and the synthesis of HIV-1 specific 
antibodies lead to a decline in the plasma viral load and a stage of clinical latency may be reached (Sierra 
et al., 2005). This stage may last 8-10 years and the individual may appear normal (Stevenson, 2003). 
However once the CD4+ T-cell count drops below 200cells/mm3 a patient experiences overt AIDS 
(Stevenson, 2003). During this final stage the virus completely takes over the immune system, the patient 
is faced with life-threatening AIDS-defining diseases which eventually leads to death (Pomerantz and 

















1.3 HIV-1 Tat Protein 
Essential, regulatory as well as accessory viral proteins play an integral role in the pathogenesis of HIV-1 
infection (Nath et al., 1998). The transactivator of transcription (Tat) protein is a key viral transactivator 
regulating gene expression from the viral promoter (Nath et al., 1998; Wallace, 2006). Tat is expressed 
early in the viral life cycle from multiple spliced viral transcripts (Schwartz et al., 1990). It is one of the 
first proteins to be expressed after infection and unlike typical DNA binding transcription factors, Tat is a 
RNA binding protein (Bagashev and Sawaya, 2013). Tat was first characterized in 1985 and was shown to 
consist of 86 or 101 amino acid and a weight of 14-16 kDa (Pugliese  et al., 2005). HIV-1 Tat has the 
ability to translocate to the nucleus of the infected cells where it plays a pivotal role in enhancing viral 
transcription (Tiwari et al., 2012). Tat can also act as an exogenous factor, having the ability to elicit a 
range of biochemical effects in various cell types (Brigati et al., 2003; Pugliese  et al., 2005). The 
pathogenicity of the virus is aggravated  by the ability of Tat to effortlessly enter target cells (Herce and 
Garcia, 2007). 
 
1.3.1 Structure of Tat protein 
Tat consists of two exons divided by an intron (Tiwari et al., 2012). The first encodes for 1-72 amino acids 
constituting five domains; an acidic domain with amphipathic characteristics, a cysteine-rich domain which 
is a metal chelating dimerization regulatory domain, a core domain which is involved in tubulin binding 
and apoptosis, the basic domain consisting of TAR-RNA binding properties and finally the glutamine-rich 
domain involved in Tat mediated apoptosis (Jeang, 1996; Tiwari et al., 2012). The second exon encodes 
for amino acids 73-101 and plays a vital role in cell adhesion and viral transcription (Jeang, 1996; Tiwari 
et al., 2012). According to Boykins et al. (1999), the 20 residue core domain sequence of Tat is sufficient 
to transactivate and induce HIV replication. 
 
1.3.2 Production of Tat protein 
Tat is essential for HIV-1 gene expression, replication and infectivity (Gavioli et al., 2002). The 
transcription process of HIV-1 is controlled primarily by Tat (Li et al., 2009; Rosen et al., 1988). 
Intracellularly, Tat augments viral transcription as its main function and exogenous Tat plays a role in 
altering gene expression and activating viral transcription in uninfected bystander cells (Tiwari et al., 
2012). Once the virus is integrated in the host genome, transcription of the HIV-1 pro-virus is characterized 
by an early and a late, Tat-independent phase of transcription (Li et al., 2009). Tat protein is produced 
during this Tat-independent phase (Li et al., 2009). In the absence of Tat, a series of short transcripts are 
produced as a result of inefficient RNA polymerase II elongation capability (Li et al., 2009). This results 
in the synthesis of a small amount of full-length viral transcripts, responsible for the production of Tat 
protein (Li et al., 2009; Yedavalli et al., 2003). 
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The Tat-dependent phase involves the augmentation of transcription, where Tat binds to the bulge of TAR 
(Transactivation response element) which is the major gene expression control centre (Figure 3) (Tiwari et 
al., 2012). TAR is found on the hairpin-loop of the 5’ terminus of the viral transcripts (Tiwari et al., 2012). 
This binding results in the formation of a stable RNA stem loop at the 5’ end of the viral transcript 
(Siddappa et al., 2006). Following this is the recruitment of the positive elongation complex (p-TEF) 
consisting of cyclin-dependent kinase 9 (CDK9) and cyclin T1 which hyperphosphorylates the carboxyl-
terminal domain of RNA polymerase II, an enzyme that enhances elongation of transcription from the viral 
promoter (Siddappa et al., 2006; Tiwari et al., 2012). This series of events lead to the production of more 
Tat forming a positive regulatory loop (Tiwari et al., 2012). Binding of Tat to TAR, cyclin T1 or CDK9 
occurs within the nanomolar range (Debaisieux et al., 2012). In the presence of Tat, gene expression from 
the viral promoter is upregulated several hundred fold (Siddappa et al., 2006). 
1.3.3 Functions of Tat protein 
Tat has effects inside the cell, where it is produced, as well as other cells that are invaded by secreted Tat. 
Inside the producing cell, Tat is able to stimulate efficient reverse transcription (Harrich et al., 1997). 
Enhanced initiation of reverse transcription occurs when Tat binds to TAR RNA, altering the structure of 
TAR (Li et al., 2009). Studies have shown that mutations on the Tat gene decreases the initiation of reverse 
transcription of HIV-1 replication by several thousand fold (Li et al., 2009). Furthermore, viruses lacking 
Tat are defective in endogenous assays of reverse transcription (Li et al., 2009). Together these results 
show that Tat is not only fundamental for regulating gene expression, but also for efficient HIV-1 reverse 
transcription (Li et al., 2009). Tat enhances the processing ability of RNA polymerase II complexes that 
would otherwise produce short transcripts, and is therefore required to stimulate proficient elongation of 
viral transcripts (Bagashev and Sawaya, 2013; Ott et al., 2004). 
Tat, by virtue of its structure, can be released from infected cells and enter uninfected bystander cells. In 
the central nervous system these cells include astrocytes, glial cells and macrophages, where it elicits 
multiple biochemical effects, thereby exacerbating immune compromise (Pugliese  et al., 2005). HIV-1 
Tat leaves infected cells via a leaderless but energy dependent pathway and extracellular Tat re-enters cells 
by binding to heparin sulfate proteoglycans (HSP) found on almost all cell surfaces (Chang et al., 1997). 
Thereafter transmembrane endocytosis occurs via the caveolae pathway (Fittipaldi et al., 2003; Vendeville 
et al., 2004). Once extracellular Tat is taken up by cells, it reaches the nucleus of the cell and modulates 
the expression of diverse cellular genes including cytokines, chemokine co-receptors, major 
histocompatibility complex (MHC) and many others, hence contributing to the overall pathogenicity of the 
virus (Siddappa et al., 2006). Tat therefore plays a vital role in HIV-1 pathogenesis, due to firstly its role 
in transactivation of viral replication and secondly, due to its action as an extracellular toxin (Campbell  
and Loret 2009). 
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1.3.4 Neurotoxic effects of Tat 
In the central nervous system (CNS) infection with HIV-1 is often associated with the development of 
dementia, a neurological disorder that is a critical cause of morbidity in a growing number of infected 
patients (Bradford et al., 1986; Price et al., 1988). HIV-1 Tat protein has been identified as a potential 
cause of this cognitive abnormality (Price et al., 1988). However, the exact mechanism by which Tat causes 
the dementia is unknown (Brabers and Nottet, 2006). Initially, studies on HIV-associated dementia (HAD) 
were directed towards an underlying opportunistic infection, however, it was later discovered that HIV 
itself infects the brain and directly causes damage to the brain (Nielsen et al., 1984; Price et al., 1988). The 
virus enters the brain during the early stages of infection, causing neuropathological changes including 
monocyte infiltration, glial cell activation and loss of neurons (Gendelman et al., 1994; Ghafouri et al., 
2006; Nath et al., 1998; Price et al., 1988).  
The concern around HAD stems from its debilitating effect on the quality of life of HIV infected persons. 
It disrupts normal function at work, daily life and even self-care (Price et al., 1988). This is due to the 
dampening and loss of motor and cognitive function which includes exaggerated tremor, unsteadiness, 
impaired fine and rapid motor control, slowed and inaccurate mental performance and other behavioral 
changes (Price et al., 1988).  
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The pathophysiological features associated with HAD include increased microglia, elevated TNF-α  
messenger RNA in astrocytes, presence of excitotoxins, decreased synaptic and dendritic density, and 
neuronal loss possibly via apoptosis (Kaul et al., 2001). The brain structures affected include the cerebrum, 
basal ganglia, thalamus, brain stem, the spinal cord and hippocampus, which explains the motor and 
cognitive dysfunction related to HAD (Price et al., 1988). Interestingly, neurons themselves are rarely 
infected directly by HIV, while astrocytes and macrophages are the most commonly infected cells in the 
brain (Nath, 2002; Pocernicha et al., 2005). Furthermore, the relation between HIV disease severity and 
viral load is not credible, while neuronal apoptosis has been found to correlate well with microglial 
activation (Adle-Biassette et al., 1999; Petito et al., 1994; Saha and Pahan, 2003). Taken together these 
observations suggest that the abnormal functioning of neurons in HAD very likely stem from indirect toxic 
mechanisms rather than HIV itself. A similar suggestion has been proposed by others (Mattson et al., 2005; 
Saha and Pahan, 2003), however the exact mechanisms has not been elucidated. 
Tat protein is released from infected cells to initiate a surge of positive feedback loops by activating 
uninfected astrocytes and microglia, causing the release of a variety of toxic substances postulated to induce 
neuronal dysfunction and cell loss (Li et al., 2009; Nath, 2002). Previous studies have suggested that 
soluble products released from infected cells, be it virotoxins or cytokines, may be toxic to neurons (Nath, 
2002). Evidence for Tat protein involvement comes from studies that show Tat transcripts to be elevated 
in HIV-1 demented brains, and both full length and first exon derived Tat are produced by HIV-1 infected 
cells of the central nervous system (Nath et al., 1998; Wesselingh et al., 1993a). The neurotoxic effects of 
Tat have now been shown to include neuronal activation, impaired synaptic function, increased 
production/release of pro-inflammatory cytokines, direct depolarization of neurons, loss of neurites and 
eventual neuronal cell death (Li et al., 2009; Nath et al., 1998). Interestingly, for these cytotoxic effects to 
occur, Tat need not be present continually (Nath et al., 1998). Instead, it seems as if the effects of Tat 
protein can be induced rapidly. In vitro studies have shown that Tat protein causes prolonged 
depolarizations of neuronal cells within a second after exposure and the secretion of cytokines from glial 
cells and macrophages can occur within minutes of exposure (Nath et al., 1998). Furthermore, Tat protein 
is capable of inducing its neurotoxic effects at picomolar levels (Kim et al., 2003). These studies show that 








Astrocytes are specialized type of glial cells which span the entire CNS (Sofroniew and Vinters, 2010).  
Astrocytes forms a homogenous cell population having a stellate morphology with extended end-feet 
processes that surround neighboring neurons and blood vessels (Sofroniew and Vinters, 2010). It also has 
intermediate filaments called glial fibrils (Kimelberg and Nedergaard, 2010; Sofroniew and Vinters, 2010). 
There are two main types of astrocytes, fibrous, which populate the white matter and protoplasmic, the 
gray matter (Molofsky et al., 2012). Fibrous astrocytes have consistent contours, cylindrical processes and 
dense glial filaments, whilst protoplasmic astrocytes have more irregular processes, few glial filaments, 
and they sheathe synapses (Molofsky et al., 2012; Sofroniew and Vinters, 2010).  
Astrocytes play a vital role in various essential CNS functions, including a supportive role to electrically 
active neurons (Kimelberg and Nedergaard, 2010; Sofroniew and Vinters, 2010). They integrate neuronal 
inputs and modulate calcium excitability, thereby influencing the activity of neighboring neurons (Araque 
et al., 2001). Being the most numerous cell type in the CNS, astrocytes have the potential to impact a wide 
range of physiological and pathological functions (Claycomb et al., 2013). 
Astrocytes lack axons and the capability to form action potentials and were thought to merely function as 
“brain glue” supporting neuronal activity (Wang and Bordey, 2008). However, astrocytes are now 
recognized to have various critical functions that contribute significantly to the form and function of the 
CNS (Wang and Bordey, 2008). Below are brief descriptions of a few well-established astrocytic functions. 
1.4.1 Astrocytes and ion homeostasis 
Astrocytes have the ability to regulate the ionic content of the extracellular space (ECS) (Wang and Bordey, 
2008). If this function is not controlled during normal neuronal activity, as a result of neurotransmission, 
the buildup of potassium ions (K+) in the ECS will cause neuronal depolarization, hyperexcitability and 
seizures (Wang and Bordey, 2008).  Astrocytes take up the excess K+ ions, distributing them through gap 
junction-coupled syncytia, and extrude ions at low extracellular K+ sites, such as directly into the blood 
stream via end-feet connections into capillaries (Figure 4) (Magistretti and Ransom, 2002; Wang and 
Bordey, 2008).  There are two proposed mechanisms by which this is done, namely by transport 
















1.4.2 Astrocytes and neurotransmission 
Unlike neurons, astrocytes are not electrically but chemically excitable (Oberheim et al., 2012). 
Accumulating evidence shows that astrocytes play direct roles in synaptic transmission, via the controlled 
release of neuroactive substances such as glutamate, ATP, adenosine, GABA and D-serine (Halassa et al., 
2007; Nedergaard et al., 2003; Sofroniew and Vinters, 2010). The release of these agents is dependent 
upon the changes in neuronal synaptic activity, involving astrocyte excitability as reflected by increases in 
astrocyte intracellular calcium concentration [Ca2+]i (Halassa et al., 2007; Nedergaard et al., 2003; 
Sofroniew and Vinters, 2010). Astrocytes express a large range of receptors, including G-protein coupled-
ionotrophic, growth factor, chemokine, steroid and Toll-like receptors (Wang and Bordey, 2008). The 
glutamate and GABA ionotrophic receptors allow astrocytes to take up and metabolize these major 
excitatory and inhibitory transmitters respectively (Kimelberg and Nedergaard, 2010; Wang and Bordey, 
2008). This ability of astrocytes shows its involvement in synaptic transmission, where the release of these 
and other gliotransmitters (Figure 4) occur in response to changes in neuronal synaptic activity (Sofroniew 
and Vinters, 2010).  The regulation of both GABA and glutamate transmitters suggests that astrocytes 
limits the spillover of glutamate and GABA from the synaptic cleft, thereby preventing inappropriate 
overstimulation of postsynaptic receptors (Wang and Bordey, 2008). This evidence suggests that astrocytes 
play direct and interactive roles with neurons during synaptic activity, which is essential in the processing 
of information by neural circuits (Araque et al., 1999; Halassa et al.,  2007; Sofroniew and Vinters, 2010). 
1.4.3 Astrocytes and CNS blood circulation 
The foot processes of astrocytes make extensive contact and have multiple bidirectional interactions with 
blood vessels, including the regulation of CNS blood flow (Figure 4) (Kimelberg and Nedergaard, 2010; 
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Sofroniew and Vinters, 2010). Recent findings show that astrocytes produce as well as release 
prostaglandins, nitric oxide and arachidonic acid, which are mediators that can increase or decrease CNS 
blood vessel diameter and blood flow in a coordinated manner (Gordon et al., 2007; Iadecola and 
Nedergaard, 2007; Sofroniew and Vinters, 2010). Changes in the CNS blood flow can consequently be 
aligned in response to changes in neuronal activity (Koehler et al., 2009; Sofroniew and Vinters, 2010). 
Astrocytes express a high level of water channels or aquaporins, namely aquaporin 4 (AQP4) (Figure 4), 
which are clustered along astrocytic processes (Sofroniew and Vinters, 2010). The connections these 
processes have with blood vessels and synapses, are central to the ability of astrocytes to regulate blood 
flow in relation to levels of synaptic activity (Sofroniew and Vinters, 2010). 
1.4.4 Astrocytes and anti-oxidation 
The CNS is continually exposed to the damaging effects of reactive oxygen species (ROS) due to its high 
rate of metabolic activity and fatty acid contents in myelin and other membranes (Kimelberg and 
Nedergaard, 2010; Sofroniew and Vinters, 2010). These ROS need to be neutralized by antioxidants and 
enzymes, however during pathological conditions, these protective mechanisms are overwhelmed and 
ROS-induced damage becomes the cause of cellular injury (Kimelberg and Nedergaard, 2010). Astrocytes 
contain a high number of several key proteins involved in neutralizing ROS, though these enzymes are not 
specifically enriched in astrocytes (Kimelberg and Nedergaard, 2010; Magistretti and Ransom, 2002). 
Because of this anti-oxidative property of astrocytes, manipulation of these cells was at one time considered 
a feasible strategy for reducing injury in several neurological diseases (Kimelberg and Nedergaard, 2010; 
Magistretti and Ransom, 2002). 
1.4.5 Astrocytes and CNS metabolism 
Astrocytes make major contributions to the metabolism of the CNS (Brown and Ransom, 2007; Sofroniew 
and Vinters, 2010). The end-feet processes are well positioned to take up glucose from blood vessels and 
supply energy metabolites to several neural elements in the gray and white matter (Figure 4) (Sofroniew 
and Vinters, 2010). Glycogen storage in the CNS occurs principally in astrocytes, and convincing evidence 
now shows that these glycogen granules serve as an energy source for neurons during hypoglycemia, when 
neuronal activity is high (Brown and Ransom, 2007). In the CNS, astrocytes are a major source of adhesion 
molecules, extracellular matrix (ECM) proteins and growth-promoting molecules (Wang and Bordey, 
2008). Astrocytes are also the source of proteolytic enzymes, like metalloproteinases, which play a role in 
ECM degradation and remodeling (Wang and Bordey, 2008; Yong et al., 1998). These cells also release 
growth factors including nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and 
fibroblast growth factor, all of which control neuronal maturation and survival (Blondel et al., 2000; Ojeda 
et al., 2000; Wang and Bordey, 2008).  
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1.4.6 Astrocytes and molecular markers 
Molecular markers are essential tools in the identification and characterization of cells (Sofroniew and 
Vinters, 2010). Astrocytes contain intermediate filaments of 9nm diameter that are composed of  glial 
fibrillary acidic protein (GFAP) (Magistretti and Ransom, 2002), a protein which is thought to be specific 
for astrocytes in the CNS (Wang and Bordey, 2008). GFAP is in fact a family of intermediate filament 
proteins that include vimentin, nestin, and others. In general, these proteins serve cyto-architectural 
functions (Sofroniew and Vinters, 2010). Expression of GFAP is considered a marker for the 
immunohistochemical identification of astrocytes (Molofsky et al., 2012; Sofroniew and Vinters, 2010) 
and has been shown to label reactive astrocytes that are responding to CNS injuries and infection (Molofsky 
et al., 2012; Sofroniew and Vinters, 2010). However, GFAP is not an absolute marker of all non-reactive 
astrocytes and is often not immunohistochemically detectable in astrocytes in healthy CNS tissue 
(Sofroniew and Vinters, 2010). Studies in transgenic mice have shown that the expression of GFAP is not 
essential for the normal appearance and function of astrocytes in the CNS, but essential for the process of 
reactive astrogliosis and glial scar formation (Pekny and Pekna, 2004; Sofroniew and Vinters, 2010). 
1.4.7 Astrocyte and neuron signaling 
Neurons have been known to signal to each other by a range of transmitter substances (Hansson and 
Ronnback, 2003). However, recent studies revealed that glial cell activity is most probably determined by 
neuronal activity, and these cells can signal to each other and back to neurons (Hansson and Ronnback, 
2003). The majority of the glial cells in the CNS are astrocytes, and as described previously, they are 
thought to play vital roles in the regulation of extracellular concentrations of ions, neurotransmitters and 
metabolites, and support neuronal and synaptic function (Hansson and Ronnback, 2003). Astrocytes 
perform neuron supportive functions including the capture of neurotransmitters from the synaptic cleft and 
the release of energy-rich substrates essential to metabolically sustain high synaptic activities (Fellin and 
Carmignoto, 2004; Magistretti and Pellerin, 1996). The position of these cells favor the conduction of 
signals between different cells in the nervous system (Araque et al., 2001). For instance, an astrocyte can 
be in contact with a neuron and a capillary simultaneously, thereby having the potential to shuffle nutrients 
and metabolites between the blood supply and the active neuron (Araque et al., 2001). Astrocytes can also 
transfer information between neighboring neurons because a single astrocyte can have contacts with 
multiple neurons (Araque et al., 2001; Halassa and Haydon, 2010 ). At an ultrastructural level, astrocytes 
have been shown to be closely associated with the neuronal synapse (Figure 4) (Araque et al., 2001) .  
Astrocyte calcium (Ca2+) signaling is one of the mechanisms by which CNS cells communicate with and 
modulate the activity of adjacent cells (Hansson and Ronnback, 2003; Pasti et al., 1997). Intracellular 
calcium concentration [Ca2+]i in astrocytes mediate the release of glutamate which triggers ionotrophic 
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glutamate receptor-mediated Ca2+ release in surrounding neurons (Fellin and Carmignoto, 2004; Parpura 
et al., 1994). The regulated increase in [Ca2+]i represents a form of astrocyte excitability (Charles et al., 
1991; Sofroniew and Vinters, 2010). Regulated increases in astrocyte [Ca2+]i are of functional significance 
in astrocyte-astrocyte and astrocyte-neuron intercellular communication (Sofroniew and Vinters, 2010). 
Astrocyte [Ca2+]i elevations can occur as intrinsic oscillations from Ca2+ released from intracellular spaces 
and can be triggered by transmitters released during neuronal activity (Halassa and Haydon, 2010 ; Perea 
et al., 2009; Sofroniew and Vinters, 2010; Volterra and Meldolesi, 2005). The elevations in [Ca2+]i may 
also elicit transmitter release from the astrocyte into extracellular spaces, which triggers receptor mediated 
currents in neurons and can be propagated to neighboring astrocytes (Halassa and Haydon, 2010 ; Perea et 
al., 2009; Sofroniew and Vinters, 2010; Volterra and Meldolesi, 2005). It is this Ca2+ signaling that enables 
astrocytes to play a direct role in synaptic transmission (Sofroniew and Vinters, 2010).  
Astrocytes express neurotransmitter receptors and transporters that have the potential to be activated by 
synaptically released neurotransmitters (Araque et al., 2001; Mennerick  et al., 1996). Astrocytes possess 
neurotransmitter receptors coupled to intracellular calcium mobilization (Araque et al., 2001). Therefore, 
due to the ability of neurotransmitters to mobilize astrocytic Ca2+, neuronal activity could regulate 
astrocytic Ca2+ levels (Araque et al., 2001). Thus, there is bi-directional signaling communication between 
neurons and astrocytes, where astrocytes not only integrate neurotransmitter inputs, but also release their 
own secretagogues that act on neighboring neurons (Araque et al., 2001).  
The release of glutamate by astrocytes may encode for two qualitatively distinct messages with diverse 
functional consequences (Fellin and Carmignoto, 2004). Glutamate release which is triggered by [Ca2+]i  
rise at the astrocyte processes, symbolizes a feedback, in the form of a short distance signal which 
influences synaptic transmission locally (Fellin and Carmignoto, 2004). Low synaptic activity triggers 
[Ca2+]i rise which is restricted to activated astrocyte processes (Fellin and Carmignoto, 2004). This short 
distance message evokes a Ca2+-dependent release of neuroactive substances in astrocytes, and this release 
works as a feedback mechanism locally affecting neuronal transmission (Fellin and Carmignoto, 2004). 
The release of glutamate and other compounds far away from the site of initial activation symbolizes a feed 
forward, long distance signal which can be implicated in the regulation of distinct processes (Fellin and 
Carmignoto, 2004). High synaptic activity sets off a Ca2+ signal that propagates to other processes and is 
oscillatory in nature (Fellin and Carmignoto, 2004). This long distance message works as a feed forward 
mechanism, transferring information on neuronal activity to other cells distant from the initial site of 
activation at the astrocyte process (Fellin and Carmignoto, 2004). 
Astrocyte–neuron signaling symbolizes an essential multifunctional unit contributing to the abundant 




1.5 Role of astrocytes in Neurological Diseases 
Astrocytes preserve a barrier between blood and the brain, providing neuronal sustenance and functions 
(Chauhan et al., 2003). Due to their vital functions, abnormal astrocyte activity may induce neuronal 
damage by loss of neuronal support functions or release of cellular products that are harmful to neurons 
(Chauhan et al., 2003). Astrocytes may also serve as a reservoir for viruses such as HIV, or release viral 
products that have deleterious effects on neurons. It is because of this latter reason that infected astrocytes 
were thought to play a role in the development of cognitive impairments associated with HIV/AIDS 
(Chauhan et al., 2003). 
Astrocytes become reactive/activated in response to a number of brain insults, including trauma, infection, 
epilepsy and neurodegeneration (Halassa and Haydon, 2010 ). During infection, this response is apparent 
by a series of morphological and functional changes that are aimed at the damaged area, producing 
immune/inflammatory responses against the invading pathogens (Rodríguez and Verkhratsky, 2010). A 
major feature of reactive astrocytes is the upregulation of GFAP, which is associated with the thickening 
of the main processes of the astrocyte (Halassa and Haydon, 2010). Reactive astrocytes are also 
characterized by hypertrophy of cell bodies and processes, altered gene expression, increases in the calcium 
binding protein S100β,  and  proliferation  that  may  occur  in  some  neurodegenerative  diseases  (Barreto et 
al., 2011).  
There are various intercellular signaling molecules that trigger reactive astrogliosis, that are released from 
surrounding astrocytes or other cell types of the CNS, including neurons, microglia, endothelia and 
pericytes (Sofroniew and Vinters, 2010). The stimulated astrocytes then cause detrimental effects such as 
cytokine production, intensification of inflammation, production of neurotoxic levels of ROS, release of 
increased excitotoxic glutamate and morphological changes that compromise blood brain barrier function 
(Brambilla et al., 2005; Sofroniew and Vinters, 2010; Swanson et al., 2004). Astrocyte activation can be 
detrimental to regenerative events following CNS injury, or beneficial in restoring the integrity of the CNS 
microenvironment (Ridet et al., 1997; Zhou et al., 2004). A balance of these two processes is deterministic 
to the development of neurologic disease or not (Ridet et al., 1997; Zhou et al., 2004). 
The pathogenesis of HIV-associated dementia (HAD) involves complex interactions between viral proteins 
and cytokines, leading to neuronal dysfunction and cell death (Nath et al., 1999). As mentioned earlier, 
HIV-1 Tat protein is the potential cause of HAD (Price et al., 1988). Astrocytes are susceptible to infection 
by HIV and neurons are rarely infected (Zhou et al., 2004). It is believed that neuronal loss in the brain of 
HIV-infected individuals result from indirect mechanisms such as the release of soluble factors including 
the HIV-1 Tat protein, from infected macrophages, microglia and/or astrocytes (Zhou et al., 2004). 
Astrocytes are of particular interest since they are non-productively infected (Brabers and Nottet, 2006). 
In these cells, viral structural protein translation is defective, and only regulatory proteins including HIV-
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1 Tat protein, are produced (Brabers and Nottet, 2006). One of the effects of Tat protein is to activate 
uninfected astrocytes to cause the release of cytokines (Nath, 2002). 
Studies have confirmed that activated astrocytes release inflammatory cytokines, tumor necrosis factor 
alpha (TNF-α)  and  interleukin-6 (IL-6) in response to certain bacterial and viral infections (Lau and Yu, 
2001). Under physiological conditions these cytokines have pleiotropic and overlapping functions and play 
vital roles in the induction and regulation of the immune and inflammatory response (Arai et al., 1990; Lau 
and Yu, 2001). TNF-α  may have neuroprotective properties, however, it has multiple damaging effects in 
the cells of the CNS including neuronal cell apoptosis and myelin damage (Chen et al., 1997). IL-6 has 
beneficial effects in the CNS because of its neurotrophic properties, however when over-expressed it can 
be detrimental, adding to the pathophysiology associated with CNS disorders (Van Wagoner et al., 1999). 
It has been shown that Tat protein stimulates the release of both IL-6 and TNF-α  from  astrocytes  in vitro 
















Cell death plays an imperative role in physiological processes; thus it is a natural part in the development 
and health of multicellular organisms (Sonker et al., 2010). Apoptosis was initially explained by Kerr et 
al. (1972) and was distinguished from necrotic cell death by detailed morphological and biochemical 
differences in dying cells (Ouyang et al., 2012). It has been recognized as a vital form of programmed cell 
death which involves the genetically determined elimination of cells (Elmore, 2007). Apoptosis is an 
important factor in normal cell turnover, proper development, function of the immune system, 
multiplication of mutated chromosomes, hormone-dependent atrophy, normal embryonic development, 
elimination of disinclined cells and maintenance of cell homeostasis  Rastogi et al., 2009; Reed and 
Tomaselli, 2000). An imbalance in apoptosis regulation has been linked to many diseases (Elmore, 2007). 
Some diseases involve insufficient apoptosis, such as cancer, and others excessive apoptosis, such as 
neurodegeneration, AIDS and autoimmune disorders (Elmore, 2007). Apoptosis therefore plays a 
significant role in proper health, but also in the onset of disease (Elmore, 2007).  
Apoptosis is achieved by 2 different signaling pathways; the intrinsic and extrinsic signaling pathways 
(Elmore, 2007). Damage of DNA, via ultraviolet radiation, ionizing radiation, viral infections, oxidative 
stress, replication or recombination errors and from environmental therapeutic genotoxins are the principle 
triggers of the intrinsic apoptotic pathway (Batista et al., 2009; Nagata, 1997; Rastogi et al., 2009), all of 
which compromise the mitochondrial membrane potential (Elmore, 2007). The extrinsic pathway can be 
induced by the binding of the death ligand to its appropriate receptor, which include members of the TNF-
α   gene   family   (Locksley et al., 2001). An additional pathway called the perforin-granzyme pathway 
induces cell death via cytotoxic T-cell killing, which is initiated by single stranded DNA damage (Elmore, 
2007). Perforin is a pore forming molecule recruited by T-cells to form a pore in the target cell (Trapani 
and Smyth, 2002). Through this pore, apoptosis inducing cytoplasmic granules called granzyme A and 
granzyme B, are released (Trapani and Smyth, 2002). The regulated control of apoptotic mitochondrial 
events is carried out by members of the B-cell lymphoma-2 (Bcl-2) family of proteins (Cory and Adams, 
2002), which can either be anti-apoptotic or pro-apoptotic (Elmore, 2007). These proteins being pro-
apoptotic or anti-apoptotic, will determine whether a cell commits to apoptosis or aborts the process 
(Rastogi et al., 2009). Apoptosis is an energy dependent process involving a group of cysteine proteases 
called caspases. It is these enzymes that link the initial stimuli to cell death (Elmore, 2007). Caspases are 
expressed in an inactive pro-enzyme form in most cells, and once activated they initiate the protease 
cascade, by activating other pro-caspases (Ouyang et al., 2012; Elmore, 2007). 
Extrinsic, death signal pathway: The tumor necrosis factor receptor (TNFR) family has a cytoplasmic 
domain of 80 amino acids called the death domain. This domain is essential in transmitting the death signal 
from the cell surface to the intracellular signaling pathway (Ashkenazi and Dixit, 1998). Examples of death 
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ligand receptor systems are TNF-α/TNFR1  and  Fas   ligand/Fas  receptor  (Rubio-Moscardo et al., 2005). 
Once the ligand binds to its receptor, cytoplasmic adapter proteins (e.g. TNFR type 1-associated death 
domain protein (TRADD)), are recruited (Ouyang et al., 2012; Elmore, 2007). The adaptor proteins have 
their own death domains and once they are recruited, they interact with the activated receptor death 
domains, forming the death inducing signaling complex (DISC) (Elmore, 2007; Sonker et al., 2010). This 
results in the auto-catalytic activation of pro-caspase-8 (Elmore, 2007; Kischkel et al., 1995) (Figure 5). 
Intrinsic, mitochondrial, non-receptor pathway: This pathway is induced by death stimuli which 
produce intracellular signals, directly affecting targets within the cell (Elmore, 2007). Viral infection, 
toxins and radiation amongst many more, cause changes in the mitochondrial membrane potential and the 
opening of the mitochondrial permeability transition pore (MPTP) (Saelens et al., 2004). This results in 
the release of the pro-apoptotic proteins such as cytochrome c (Saelens et al., 2004). This leads to the 
formation of an apoptosome by the interaction of cytochrome c with apoptotic protease activating factor 1 
(Apaf-1) molecules (Romani et al., 2010). The apoptosome converts the initiator protein pro-casapase-9 to 
caspase-9 (Romani et al., 2010) (Figure 5). 
Perforin-granzyme pathway: This pathway involves the release of perforin from cytotoxic T-
lymphocytes to activate granzyme B and A (Elmore, 2007). Granzyme B converts pro-caspase-10 to 
caspase-10 which subsequently cleaves the initiator protein pro-caspase-3 to form caspase-3 (Elmore, 
2007). Granzyme A activates caspase-independent pathways and cleaves the nucleosome assembly protein 
(SET) which initiates DNA cleavage (Elmore, 2007) (Figure 5). 
The intrinsic, extrinsic and the granzyme B dependent pathways all terminate on the same execution 
pathway, which starts with pro-caspase-3 (Ouyang et al., 2012). Once caspase-3, the most vital execution 
protein, is activated by initiator caspases-8, 9 or 10, the final phase of apoptosis begins (Elmore, 2007). 
Cellular disruption involves a sequence of events which include endonuclease activation, DNA 
fragmentation, activation of proteases that degrade nuclear proteins, formation of apoptotic bodies, 
cytoplasmic blebbing and lastly, the phagocytosis of the blebbed contents by neighboring macrophages 
















   
 
1.6.1. TNF-α  and IL-6 induced neuronal apoptosis 
As mentioned previously, HIV-1 appears to act via indirect mechanisms to induce neuronal cell death (Saha 
and Pahan, 2003). HIV-1 leads to the loss of CD4 cells resulting in immunodeficiency, whilst the immune 
profile in the brain suggests an immune activation involving mediators produced by macrophages and 
astrocytes (Mattson et al., 2005; Wesselingh et al., 1994). Studies have shown the increased production of 
TNF-α,  IL-6, IL-1β  and  other   chemokines   in   the  brains  of   individuals  with  HIV  infection  (Chen et al., 
1997; Conant et al., 1998; Wesselingh et al., 1993b). 
Pro-inflammatory cytokines have both beneficial and detrimental effects in the CNS depending on the 
circumstances under which they are secreted (Sheng et al., 2005). These cytokines are involved in the 
immune response to infection and directly influence neuronal function (Hagberg and Mallard, 2005; 
Nimmervoll et al., 2012). The major pro-inflammatory cytokine, TNF-α  and  its  receptors  are  expressed  at  
nominal levels in all types of brain cells under normal conditions, supporting its physiological role in brain 
functioning (Perry et al., 2002; Saha and Pahan, 2003). However, studies have shown strong evidence of 
TNF-α   and   its   receptors   in   the   pathogenesis   of   HIV   related   cognitive   abnormalities   and   other  
neurodegenerative disorders (Saha and Pahan, 2003).  TNF-α  can  elicit  both  autocrine  and  paracrine  effects  
on surrounding cells which in turn can lead to a positive feedback loop, leading to additional cytokine and 
chemokine production (Hanisch, 2002; Sheng et al., 2005). Not only can this cytokine elicit inflammation, 
it can also induce apoptosis via its receptor and intracellular signaling pathways (Muppidi et al., 2004; 
Sheng et al., 2005; Wajant et al., 2003). The homeostatic role of TNF-α   is   to   control   the   equilibrium 
between neuronal excitation and inhibition (Nimmervoll et al., 2012; Stellwagen and Malenka, 2006). 
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Studies have shown that TNF-α  is  also  implicated  in  neuronal  cell  death  (Araki et al., 2001; Block et al., 
2004; Nimmervoll et al., 2012), and therefore, the interaction between neuronal activity and TNF-α  may  
control cell death and survival processes in developing neuronal networks (Nimmervoll et al., 2012). 
Studies have shown that TNF-α  causes  cell  death  mainly  via  the  extrinsic  apoptotic  pathway,  exerting  its  
effects via 2 receptor subtypes situated on the target cell membranes: TNFR1 and TNFR2 (Cabal-Hierro 
and Lazo, 2012; Guadagno et al., 2013). The association of Fas-Associated protein with death domain 
(FADD) to TNFR1 bound Tumor necrosis factor receptor type 1-associated death domain protein 
(TRADD) recruits pro-caspase-8 by protein-protein interaction via homologous death effector domain 
(DED) (Saha and Pahan, 2003). The death inducing signaling complex (DISC) is formed during which 
pro-caspase-8 is autolytically cleaved, liberating caspase-8 from DISC (Saha and Pahan, 2003). Following 
this the caspase cascade is triggered which includes the activation of effector caspases-3, 6 and 7 (Saha 
and Pahan, 2003). This leads to the death of the cell (Fotin-Mleczek et al., 2002; Saha and Pahan, 2003).  
Interleukin-6 is a pleiotropic cytokine having various biological activities in immune regulation, 
hematopoiesis, inflammation and oncogenesis (Kishimoto, 2010). This cytokine regulates various 
physiological events including cell proliferation, differentiation, survival and apoptosis (Figure 6) 
(Guzmán et al., 2010). In general, it is regarded as a pro-inflammatory cytokine, but it also possesses anti-
inflammatory properties (Scheller et al., 2011). IL-6 provides survival to neurons, astrocytes and 
oligodendrocytes in cases of brain injury and disease (Rincon, 2012). While this cytokine has beneficial 
effects, it may also generate unwanted consequences causing the pathophysiology associated with CNS 
disorders (Van Wagoner et al., 1999). Studies have shown the pathological roles of IL-6 in various disease 
conditions, like inflammatory, autoimmune, neurological and malignant diseases (Kishimoto, 2010; 
Kishimoto and Ishizaka, 1971; Rincon, 2012). Increased levels of IL-6 in the CNS have been demonstrated 
in several neurological diseases and in HIV infection (Qiu et al., 1998). Despite these numerous studies, 
its exact role in the progression of these diseases remains unclear (Rincon, 2012). It has been suggested 
that elevated levels of IL-6 in the CNS in neurological disorders may be a contributing factor to 
histopathological, pathophysiological, and cognitive defects related to these disorders (Guzmán et al., 
2010). Hence, chronic exposure to IL-6 seems able to interrupt normal functioning of the CNS.  
Astrocytes are a major source of IL-6 in the CNS (Van Wagoner et al., 1999). These cells produce large 
quantities of IL-6 when stimulated (Lee et al., 1993) and may therefore be important sources of IL-6 in 
CNS disease (Qiu et al., 1998). As mentioned earlier, CNS neurons and astrocytes are closely linked, and 
neurons are likely to be exposed to high concentrations of IL-6 under pathological conditions (Qiu et al., 
1998). The N-methyl-D-aspartate receptor (NMDAR) is a highly Ca2+-permeable, ligand gated ion channel 
found in neurons and is a member of the ionotropic glutamate receptor family (Kaul and Lipton, 2000). 
Chronic exposure of neurons to IL-6 enhances NMDA receptor mediated intracellular calcium signals and 
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Figure 6. Schematic representation of IL-6 function in apoptosis and proliferation (Steiner, 2009). 
increases resting calcium levels (Holliday et al., 1995; Qiu et al., 1995; Qiu et al., 1998). The results of 
these studies implicate NMDAR and intracellular calcium as important mechanisms through which IL-6 
alters neuronal function (Qiu et al., 1998). Excessive Ca2+ accumulation after NMDAR stimulation leads 
to depolarization of the mitochondrial membrane potential and reduces the cellular ATP concentration 
(Kaul and Lipton, 2000). If the initial insult is severe, cells do not restore the ATP levels and subsequently 
die a necrotic death due to the loss of ionic homeostasis (Kaul and Lipton, 2000). When the initial insults 
are mild, ATP levels can be recovered to some extent, but these cells often undergo apoptosis (Kaul and 
Lipton, 2000).  
Studies have shown both that IL-6 possesses pro-inflammatory, anti-inflammatory, neuroprotective and 
neurotoxic effects (Guzmán et al., 2010; Rincon, 2012; Scheller et al., 2011). These contrasting views 













1.7. Anti-retroviral therapy 
AIDS is by far the most dreadful endemic experienced by mankind to date (Karn, 1999). HIV, the virus 
causing AIDS, results in a chronic infection for which there is no cure (Arts and Hazuda, 2012). This 
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creates great challenges for sustaining lifetime patient therapy (Arts and Hazuda, 2012). Original 
antiretroviral (ARV) therapy consists of reverse transcriptase inhibitors and/or protease inhibitors (Arts 
and Hazuda, 2012). These drugs target two of the essential enzymes required for the replication of HIV 
(Arts and Hazuda, 2012; Karn, 1999). A combined treatment including both these agents therefore 
suppresses viral replication and drops the plasma viral load to levels that are lower than the confines of 
detection by the most sensitive clinical assays (Arts and Hazuda, 2012). While combined therapy (also 
referred to as highly active antiretroviral therapy (HAART)), can suppress viral replication and increase a 
patient’s life-span, it is unable to completely eliminate the HIV-1 infection (Arts and Hazuda, 2012). 
Subsequently clinicians managing people infected with HIV are constantly faced with the problem of a 
residual reservoir of the virus. 
Besides the residual viral load problem, treatment with ARV’s can also be impaired by non-adherence, 
poor drug tolerability and interactions between other medication and ARV agents (Arts and Hazuda, 2012; 
Bhattacharya and Osman, 2009). Factors such as these have been proposed to contribute to the evolution 
of drug resistance in these patients (Arts and Hazuda, 2012; Bhattacharya and Osman, 2009). Drug 
resistance has led to extensive research in novel managements for HIV-1 infection (Bhattacharya and 
Osman, 2009). There have been new targets approved for HIV-1 treatment, including chemokine receptor 
antagonists, nucleoside analogs, integrase inhibitors and maturation inhibitors (Arts and Hazuda, 2012; 
Bhattacharya and Osman, 2009). Agents acting on the HIV-1 proviral DNA, Tat-TAR interaction inhibitors 
and HIV-1 envelope oxidizers are targets amongst others which are in various clinical stages of 
development (Bhattacharya and Osman, 2009). Given this range of treatment, it is hoped that patients can 
be more successfully treated (Arts and Hazuda, 2012). Despite these therapeutic advances, the virus 
manages to evolve and evade the most effective therapy, essentially forcing the scientific community to 
continue their search for new HIV-1 treatments (Arts and Hazuda, 2012). At present novel ARV drugs are 
not considered a substitute for the original ARV’s, since basic ARV treatment remains the chief support in 
managing HIV-1 (Bhattacharya and Osman, 2009). 
There are also other challenges that persons living with HIV face. HAART does not offer complete 
protection against HIV/AIDS induced neurological damage (Palacio et al., 2012). The availability of 
HAART has decreased the occurrence of HAD and the clinical manifestations are less severe (Mattson et 
al., 2005). However, due to increased rates of patient survival, the rate of HAD incidence continue to rise 
(Mattson et al., 2005). Control of HIV-1 in the CNS is still imperative because in some patients the control 
of the virus in the periphery is exceptional whilst cognitive decline persists (Mattson et al., 2005). Increased 
viral loads can be identified in the cerebrospinal fluid of infected patients due to poor penetration of ARV’s 
across the blood-brain barrier and viral advancement in the brain (Mattson et al., 2005). Available ARV’s 
have no effect on the production of non-structural proteins like Tat, which continues production and release 
from infected cells like astrocytes (Mattson et al., 2005). Since HAART is insufficient in the treatment of 
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HAD, other targets include both structural and regulatory viral proteins, and the various steps involved in 
the pathogenesis of HAD (Nath, 2002).  
Although HAART improves the lifespan of an infected individual, the effect of the drugs itself as well as 
the secondary complications from chronic infections, is causing the quality of life to decline (Bagashev 
and Sawaya, 2013). Therefore, there is plenty more to discover in the mission of controlling HIV (Bagashev 
and Sawaya, 2013). For this it is important to understand, at a molecular level, how the virus and its proteins 
influence cells (Bagashev and Sawaya, 2013). This will offer the opportunity to create additional 
therapeutic strategies that may facilitate the attenuation of HIV and HIV associated pathologies (Bagashev 


















1.8 Hypothesis  
Since astrocytes are the main target of HIV infection in the CNS and because of the intimate functional 
interaction between astrocytes and neurons, we hypothesized that 
 HIV-1 Tat protein alone is sufficient to activate astrocytes, 
 Once astrocytes become activated, they release TNF-α  and  IL-6,  
 Released TNF-α  and  IL-6 may be harmful to neurons, and initiate neuronal cell death via apoptosis. 
1.9 Aims 
In order to prove our hypothesis, we formulated the following aims: 
 To determine whether commercial Tat is biologically active. 
 To determine whether Tat activates astrocytes. 
 To establish whether astrocytes exposed to Tat, results in the release of IL-6 and TNF-α. 








To test our hypothesis that Tat stimulates astrocytes to release IL-6 and TNF-α  and  that  these  cytokines  
induce apoptosis in neurons, we asked the following questions: 
1. Do astrocytes release IL-6 and TNF-α  upon  stimulation  by  Lipopolysaccharide (LPS) (that 
served as a positive control) and Tat? 
2. Can IL-6 and TNF-α  released  in  the  medium  in  which  the  astrocytes  were  grown,  induce  
apoptosis in neurons? 
 
2.2 Cell lines  
Cell lines, CRL 2137 (Human Neuroblastoma), U87.CD4.CCR5 (Human Astroglioma) and reporter CEM-
GFP (Human T-cell, CD4+ Lymphoblastiod) cell lines were generous gifts from Dr D. Ramsuran of 
KwaZulu-Natal Research Institute for TB and HIV (K-RITH). 
2.2.1 Culturing CEM-GFP cells 
CEM-GFP cell lines were grown in Roswell Park Memorial Institute-1640 (RPMI-1640) medium (Lonza, 
Basel, Switzerland), supplemented with 10% Fetal Bovine Serum (Biochrom, Merck Millipore, Darmstadt, 
Germany), penicillin and streptomycin (100 mg/ml) and L-Glutamine (PAA, Pasching, Austria); this 
constituted complete culture medium. The cells were incubated in a CO2 water jacketed incubator (Shel 
Lab, Oregon, U.S.), at 37°C in a 95% humidified atmosphere containing 5% CO2. 
2.2.2 Culturing CRL and U87 cells 
CRL and U87cells were grown in Dulbecco’s Modified Minimal Essential Medium (DMEM) medium 
(Lonza, Basel, Switzerland), supplemented with 10% Fetal Bovine Serum (Biochrom, Merck Millipore, 
Darmstadt, Germany), penicillin and streptomycin (100 mg/ml) and L-glutamine (PAA, Pasching, 
Austria); this constituted complete culture medium for these cells. The cells were grown in a CO2 water 
jacketed incubator (Shel Lab, Oregon, U.S.), at 37°C in a 95% humidified atmosphere containing 5% CO2. 
Trypan Blue (Bio-Rad, Hercules, CA) was used as an exclusion dye for viable cell counting. All cell lines 
were counted using an Automated Cell Counter (Bio-Rad, Hercules, CA). Cells were cultured in 25 and 
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Light micrograph of U87 cell line at a 20X magnification 
 
Light micrograph of CRL cell line at a 20X magnification 























2.3. Biological activity of commercially procured HIV-1 Tat protein 
BioPORTER reagent transfection of HIV-1 clade B Tat protein (Tat) into CEM-GFP reporter cell lines 
were done to determine whether Tat was biologically active. Here 10μg/ml  of  Tat  (Diatheva,  Fano,  Italy)  
(Appendix 1) was delivered into CEM-GFP cells after formulation with the BioPORTER reagent (Gene 
Therapy Systems, San Diego, USA). The summarized protocol for the transfection is shown in Table 2 (as 
per BioPORTER reagent instruction manual). 




250µl methanol was added to the BioPORTER reagent. 
Vortexed at top speed for 20secs. 
2.5µl was aliquoted into 1.5ml Eppendorf tubes. 
9 of the Eppendorf tubes with BioPORTER reagent was left under a laminar 




HIV-1 Tat protein was resuspended in 200µl PBS (Sigma, Missouri, USA) 
(Appendix 2). 
25µl diluted Tat protein solution was added to 3 of 9 BioPORTER reagent 
Eppendorf tubes. 
Tubes with BioPORTER/protein complex were mixed 3-5 times by pipetting. 
The tubes were left to stand at room temperature for 5mins and then vortexed 
gently for 3-5 secs. 
225µl serum free medium was added to the BioPORTER/protein complex, 





10µl (1ng/ml) Fluorescein isothiocyanate (FITC) antibody (provided by kit) 
was added to 3 of the 6 remaining BioPORTER reagent Eppendorf tubes.  




The tubes were left to stand at room temperature for 5mins and then vortexed 
gently for 3-5 secs. 
240µl serum free medium was added to the BioPORTER/protein complex, 
bringing the final volume to 250µl. 
Cell culture 
preparation 
The CEM-GFP cell suspension was centrifuged (Beckman Coulter, Brea 
California) at 1200rpm for 5mins and resuspended in serum free medium. 
Cells were counted and 1x106cellswere transferred to the final delivery mix 
of each of the 9 BioPORTER reaction tubes. 
BioPORTER/negative 
control 
The remaining 3 tubes contained cells and BioPORTER reagent only 
Transfer and 
incubation 
Each reaction was transferred to a 24 well plate (Figure 7) 
The plate containing the reactions was incubated for 3-4 hours at 37°C. 
1ml serum containing medium was added to each reaction after 3-4 hours. 








A1-A3 = Control: untreated cells only 
B1-B3  =  Positive control: 1ng/ml FITC 
antibody 
D1- D3 = Cells exposed to 10µg/ml Tat 
 
Figure 7. A 24-well tissue culture plate seeded with CEM-GFP and transfected CEM-GFP cells for Tat 
biological activity testing. 
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2.3.1 Microscopic analysis 
The emission of green fluorescence by CEM-GFP cells exposed to Tat was viewed as a wet preparation 






















2.4 Tat stimulation of astrocytes 
Western blot assays were used to determine whether U87 cells were activated upon exposure to HIV-1 B 
Tat. Here U87 cell lines were seeded onto 24-well tissue culture plates (1 x 106 cells per well with 500µl 
medium) and exposed to either 1µg/ml Lipopolysaccharide (LPS) (Sigma, Missouri, US) (Appendix 3) or 







Following overnight incubation, cells were detached using Trypsin EDTA (PAA, Pasching, Austria), 
collected in 1.5ml Eppendorf tubes (BD Biosciences, San Jose, CA), and spun down at 1500rpm for 5mins 
in a Microfuge 16 Centrifuge (Beckman Coulter, Brea, CA). The supernatant was discarded and pellets 
were lysed using 150µl 1% sodium dodecyl sulphate (SDS) (Sigma, Missouri, US), samples were shaken 
on a sunflower mini shaker (Grant Instruments, Cambridge, UK) at low speed for 10mins. Laemmli Sample 
Buffer (Bio-Rad, Hercules, CA) was added to cell lysates (Table 3). 
Table 3. Sample buffer and cell lysate volumes. 
Sample Sample volume (µl) Laemmli Volume (µl) 
Untreated U87 cells 7 4 
U87 cells exposed to LPS 8 4.5 
U87 cells exposed to Tat 15 7 
 
U87 cell lysate with Laemmli was placed in a Thermomixer (Eppendorf, Hamburg, Germany), for 10mins 
at 95°C. The cells were then centrifuged at 16 000 rpm for 1min. 
A1, A3 = Control: untreated cells only 
B1-B3  = Positive control: 1µg/ml  LPS 
D1-D3 = 10µg/ml Tat  
Figure 8. A 24-well tissue culture plate seeded with U87 and exposed to 1µg/ml LPS or 10µg/ml Tat for 
western blot analysis of GFAP. 
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2.4.1 Preparing and running of Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) Gels. 
The Tris-Glycine extended (TGX) and TGX stain-free “fast cast” Acrylamide kit (Bio-Rad, Hercules, 
CA) was used to cast the Sodium Dodecyl Sulfate Polyacrylamide (SDS-PAGE) gel. 
SDS-PAGE gel. The resolving and stacking gels were made as shown in Table 4. 
Table 4. Preparation of SDS-PAGE Resolving and Stacking Gel. 
Resolving gel (7.5%) 
Constituent Volume 
Resolver A  3ml 
Resolver B 3ml 
Tetramethylethylenediamine (TEMED) 3µl 
10 % Ammonium Persulfate (APS) (Appendix 20) 30µl 
Stacking gel (4%) 
Stacker A 1ml 
Stacker B 1ml 
TEMED 2µl 
10% APS 10µl 
The resolving gel was pipetted into a glass gel holder and the stacking gel was carefully pipetted on top of 
the resolving gel. A 10 well comb was carefully placed on top of the stacking gel and the gel was left to 
polymerize for 45mins. Once the gel polymerized, the comb was removed and the gel was firmly placed 
onto a running module (Bio-Rad, Hercules, CA), with the buffer dam (Bio-Rad, Hercules, CA) on the 
opposite side and subsequently placed in the buffer tank (Bio-Rad, Hercules, CA). The tank was filled with 
1X Tris-Glycine-SDS running buffer (Bio-Rad, Hercules, CA) (Appendix 4) to the “2 blot” point. The 
wells were washed twice with buffer. In the first lane, 4µl of Precision Plus Protein Dual Xtra (Bio-Rad, 
Hercules, CA) molecular marker was added. The samples prepared as shown in Table 3, were added to the 
wells. The gel ran at 150V and 3Amps for 45mins. 
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Figure 9. Pre-transfer gel stain-free image captured as image A on the ChemiDoc MP system (Image A was 
used to assess the sample integrity and separation quality). 
Following the run an image of the pre-transfer gel (Figure 9) was captured using the ChemiDoc MP system 











2.4.2 Transfer of SDS-PAGE gel to nitrocellulose membrane and antibody treatments 
Following the run, the gel was removed from the glass gel holder. Two separate blotting papers and a 
nitrocellulose membrane (Bio-Rad, Hercules, CA) were soaked in 1X Tris-Glycine (TG) transfer buffer 
(Bio-Rad, Hercules, CA) (Appendix 5) for 10mins. The first blotting paper was placed onto the tray of the 
Trans-Blot Turbo (Bio-Rad, Hercules, CA) and the membrane was placed over it. The gel was placed onto 
a membrane and covered with the second blotting paper and ran for 10mins at 2.5A and 25V. After the 
transfer the gel and blot was placed in deionized water. The post-transfer stain-free gel (Figure 10) and blot 












Figure 10. Post- transfer gel stain-free image captured as image B on the ChemiDoc MP system (Image B 
was used to measure the transfer efficiency of the samples). 
Figure 11. Post-transfer blot stain-free image captured as image C on the ChemiDoc MP system. Image 


































After the transfer, the procedure in Table 5 was followed. 
Table 5. Antibody, blocking treatments and washes. 
Process Method 
Wash 
The blot was washed 3X for 10mins on a sunflower mini shaker with 1X 
Tris-Buffered Saline (TBS) (Bio-Rad, Hercules, CA) wash buffer 
(Appendix 6). 
Blocking 
20ml of 5% Bovine Serum Albumin (BSA) (Roche Diagnostics, Basel, 
Switzerland) blocking buffer was added to the blot (Appendix 7), and left 
on shaker for 2 hours. 
Primary Antibody 
After calibration, the suitable Primary Anti-GFAP Antibody (Abcam, 
Cambridge, UK) solution was prepared at a dilution of 1:714 (Appendix 
8), added to the blot and incubated at 4 C overnight. 
Wash 
The antibody solution was removed and the blot was washed 3X for 
10mins on a shaker with TBS. 
  Secondary Antibody 
After calibration, the suitable Antibody (Abcam, Cambridge, UK) solution 
was prepared at a dilution of 1:11000 (Appendix 9), added to the blot and 
incubated for an hour on a shaker. 
Wash The blot was washed 3X for 10mins on a shaker with TBS. 
The Clarity Western ECL Substrate includes Clarity western peroxide reagent and Clarity western 
lumino/enhancer reagent (Bio-Rad, Hercules, CA). 6ml of each reagent was mixed and added to the blot. 
The blot was left to soak in the reagents for 5mins and then the chemiluminescent blot was captured using 
the ChemiDoc MP system. 
 
2.4.3 Loading control and protein normalization 
The normalization factor and normalized volume were performed automatically by the ChemiDoc MP 
software using the chemiluminescent and the post-transfer stain-free blot images. The target protein band 
intensity values were adjusted for any variations in the protein load, allowing for accurate comparison of 
target protein among the samples.  
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2.5 Release of IL-6 and TNF-α  by  astrocytes 
ELISA assays were used to assess whether U87 cells release IL-6 and TNF-α   into   the  medium upon 
exposure to LPS or Tat.                                                                   
   
2.5.1 TNF-α  detection 
U87 cells were seeded onto a 24-well tissue culture plate (1 x 106 cells per well with 500µl medium). 2 
hours prior to LPS or HIV-1 B Tat exposure, medium from each well was discarded and serum free medium 
was added. 2 hours later, U87 cells were treated as in Figure 8. Following a 1 hour incubation period (Chen 
et al., 1997), the medium from each sample was pooled, spun down and the supernatant was processed 
according to Human TNF-α  ELISA  Max Deluxe package inserts (BioLegend, San Diego, CA), protocol 
summarized in Table 6. 
 
Table 6. ELISA protocol 
Procedure Method 
 All the reagents were brought to room temperature before use. 
 Plates were washed in an Immunowash Microplate Washer (Bio-Rad, Hercules, CA). 
 Plates were shaken on a Rocker Shaker PMR 100 (Grant Instruments, Cambridge, UK) at 200rpm. 
Coating Plates 
The 5X Coating Buffer was diluted (Appendix 10) 
The Capture Antibody was diluted with 1X coating buffer (Appendix 11) 
The plate was coated with 100µl of Capture Antibody and incubated for 18 hours 
at 4 °C 
Wash The plate was washed 4X with 300µl wash buffer (Appendix 12). 
Blocking 
The 5X Assay Diluent was diluted (Appendix 13) and 200µl of 1X Diluent Assay 
was added to each well of the plate. 
The plate was incubated for 1 hour at room temperature on a shaker. 
Wash The plate was washed 4X with 300µl wash buffer 





100µl of standards and samples were added to the appropriate wells (Figure 12) 
and incubated for 2 hours at room temperature on a shaker. 
Wash The plate was washed 4X with 300µl wash buffer 
Detection 
Antibody 
The Detection Antibody was diluted (Appendix 15) and 100µl was added to each 
well 
The plate was incubated at room temperature for 1 hour on a shaker 
Wash The plate was washed 4X with 300µl wash buffer 
Avidin-HRP 
Avidin-HRP was diluted (Appendix 16) and 100µl was added to each well 
The plate was incubated at room temperature for 30mins on a shaker 
Wash  Washed plate 5X with 300µl wash buffer, plate washer 
TMB Substrate 
Fresh Substrate was prepared (Appendix 17) and 100µl was added to each well 
The plate was incubated at room temperature, in the dark for 15mins 


















After the reaction was stopped by the addition of the stop solution the absorbance values were read within 
30mins at 450nm, using the BioTek plate reader and Gen5 2.0 software (BioTek, Winooski, US). Gen5 2.0 
software generated the optical density values from which a standard curve was formulated to calculate the 
concentrations of TNF-α  in  the  samples. 
 
2.5.2 IL-6 detection 
U87 cell lines were seeded onto a 24-well tissue culture plate (1 x 106 cells per well with 500µl medium). 
2 hours prior to LPS or Tat exposure, medium from each well was discarded and serum free medium was 
added. 2 hours later, U87 cells were treated as in Figure 8. Following a 1 hour incubation period (Nath et 
al., 1999), the medium from each sample was collected and the supernatant was processed according to 
Human IL-6 ELISA Max Deluxe package inserts (BioLegend, San Diego, CA), protocol summarized in 
Table 6. 











Negative control (Cells 
only) 
3B-3H, 4B-4H, 5B-5H 
Positive control 
(100ng/ml LPS) 
6B-6H, 7B-7H, 8B-8H 






2.6 IL6 and TNF-α  induced  apoptosis  in  neurons 
Flow cytometry including Annexin V and caspase-3 assays were used to assess whether exogenous IL6 
and/or TNF-α  could induce apoptosis in neurons. 
 
2.6.1 Fluorescein isothiocyanate (FITC) Annexin V assay 
CRL cells lines were seeded onto 24-well tissue culture plates (1 x 106 cells per well with 500µl medium). 
2 hours prior to IL-6 and/or TNF-α  (BioVision, Milpitas, CA) (Appendix 21) exposure, medium from each 
well was discarded and 500µl serum free medium was added. 2 hours later, cells were treated as in Figure 
13. 10µM Camptothecin (Sigma, Missouri, U.S) (Appendix 18) was used as a positive control for 
apoptosis. The positive control was created over 8 wells for the purpose of electronic compensation. Cells 









2.6.1.1 Cell staining with FITC Annexin V 
Apoptosis induction by cytokines IL-6 and TNF-α  in  CRL  cells  were  evaluated  using  the  FITC  Annexin  
V Apoptosis Detection Kit (BioLegend, San Diego, CA). Following an overnight incubation period, CRL 
cells were detached using trypsin and washed twice with cold Cell Staining Buffer (BioLegend, San Diego, 
CA). Cells were then resuspended in 100µl Annexin V binding buffer (included in the kit), transferred to 
FACS tubes (Becton Dickenson, San Jose, CA) and stained according to the package insert, summarized 




A1-A5 = Control: untreated cells only 
A6-B6 =  Positive control: 10µM Camptothecin  
C1-C3 = 100ng/ml Recombinant TNF-α 
C4-C6 = 100ng/ml Recombinant IL-6 
D1-D3 = 100ng/ml Recombinant IL-6 and TNF-α 
Figure 13. A 24-well tissue culture plate seeded with CRL cells for FITC Annexin V analysis. 
   
 
Table 7. Staining cells using FITC Annexin V kit. 
Cells Stain No. of samples 
Control: Untreated cells 
Unstained 2 
5 µl FITC Annexin + 10 µl Propidium Iodide 
(PI) 
3 
Positive Control : 10µM 
Camptothecin 
5 µl FITC Annexin + 10 µl PI 3 
5 µl FITC Annexin 2 
10 µl PI 2 
100ng/ml Exogenous TNF-α 
 
5 µl FITC Annexin + 10 µl PI 
 
3 
100ng/ml Exogenous  IL-6 
 
5 µl FITC Annexin + 10 µl PI 
 
3 
100ng/ml Exogenous IL-6 
and TNF-α 
 
5 µl FITC Annexin + 10 µl PI 
3 
 
Cells were gently vortexed and incubated for 15 minutes in the dark, at room temperature. 
 
2.6.1.2 Flow cytometric data acquisition and data analysis 
After incubation, 400µl Annexin V Binding Buffer was added to each sample. Cells were then analyzed 
on a LSR Fortessa SORP Flow Cytometer (Becton Dickenson, San Jose, CA) using a 488nm excitation 
and 530/30nm band pass filter for fluorochrome FITC detection, and 561nm laser excitation and band pass 
filter 610/20 for fluorochrome Propidium Iodide (PI) detection. Electronic compensation of the instrument 
was performed using single stain samples to exclude overlapping of the two emission spectra.  
Acquisition of data was followed by analysis which was performed using FACS Diva v7.0 (Becton 
Dickenson, San Jose, CA). For each concentration, 50 000 cells were analyzed for the detection of 
apoptosis. 
2.6.2 Phycoerythrin (PE) active caspase-3 assay 
CRL cells were seeded onto a 24-well tissue culture plate (1 x 106 cells per well with 500µl medium). 2 
hours prior to IL-6 and/or TNF-α  exposure,  medium from each well of cells were discarded and 500µl 
   
 
serum free medium was added. 2 hours later, cells were treated as in Figure 14. 10µM Camptothecin 







2.6.2.1 Cell staining for caspase-3 detection 
Apoptosis induction by cytokines IL-6 and TNF-α  in  CRL  cells  was  evaluated  using  the  pycoerythrin (PE) 
Active Caspase-3 Apoptosis Kit (Becton Dickenson, San Jose, CA USA). Following 4 hours of incubation 
cells were detached using trypsin and stained according to manufacturer’s procedure. A summarized 
protocol is shown in Table 8. 
Table 8. Staining cells using PE active Caspase-3 apoptosis kit. 
Process Method 
Wash 2X (PBS) 
After detachment, cold PBS was added to cells and cells were 
centrifuged at 1500rpm for 5mins. 
The cells were resuspended in 500µl BD Cytofix/Cytoperm and 
incubated on ice for 20mins. 
Wash 2X (BD Perm/Wash Buffer) 
The cells were then centrifuged at 1500rpm for 5mins 
The supernatant was removed and the pellet was resuspended in 
0.5ml 1X Perm/Wash Buffer (Appendix 19). 
The cells were centrifuged again at 1500rpm for 5mins 
A1-A5 = Control: untreated cells only 
B1-B3 =  Positive control: 10µM Camptothecin  
C1-C3 = 100ng/ml Recombinant TNF-α 
C4-C6 = 100ng/ml Recombinant IL-6 
D1-D3 = 100ng/ml Recombinant IL-6 and  TNF-α 
Figure 14. A 24-well tissue culture plate seeded with CRL cells for caspase-3 analysis. 
   
 
Staining (PE Anti-Active caspase-
3 antibody) 
The cells were then resuspended in 100µl BD Perm/Wash Buffer 
20µl PE rabbit anti-active caspase-3 antibody was added to each 
sample excluding the control group and incubated for 30mins at 
room temperature 
Wash (BD Perm/Wash Buffer) 
1ml BD Perm/Wash Buffer was added to each test  
The cells were centrifuged at 1500rpm for 5mins 
The cells were resuspended in 500µl BD Perm/Wash Buffer 
 
 
2.6.2.2 Flow cytometric data acquisition and data analysis 
Cells were then analyzed on a LSR Fortessa SORP Flow Cytometer using 561nm filter excitation and 
610/20nm band pass filter for fluorochrome PE-A detection. Electronic compensation of the instrument 
was performed using single stain samples to exclude overlapping of the two emission spectra. 
Acquisition of data was followed by analysis which was performed using FACS Diva v7.0. For each 










2.7 Induction of apoptosis in neurons by Tat stimulated astrocytes 
Flow cytometry including Annexin V and caspase-3 assays were used to assess whether the medium of 
U87 cells treated with Tat induced apoptosis in CRL cells. 
 
2.7.1 Fluorescein isothiocyanate (FITC) Annexin V assay 
U87 and CRL cells were grown to confluence and seeded onto 2 separate 24-well tissue culture plates (1 
x 106 cells per well with 500µl medium) (Figure 15 and 16). 2 hours prior to HIV-1 B Tat or LPS exposure, 
medium from each well of U87 cells were discarded and 250µl serum free medium was added. 2 hours 
later, U87 cells were treated as in Figure 15. Following a 1 hour incubation period (similar to the incubation 
period mentioned in 2.5.1 and 2.5.2) the U87 cell medium was collected and centrifuged at 1500rpm for 
5mins. CRL cell medium was discarded. Medium from U87 cells were pooled and added to the CRL cell 
lines (Figure 16). 10µM Camptothecin (Appendix 18) was used as a positive control for apoptosis (Figure 
16). The positive control was created over 7 wells for the purpose of electronic compensation. CRL cells 










A1-A4 = Control: untreated cells only 
B1-B4 =  Positive control: 10µM Camptothecin  
D1-D4=  10µg/ml Tat  









2.7.1.1 Cell staining with FITC Annexin V 
Apoptosis induction in CRL cell lines was evaluated using the FITC Annexin V Apoptosis Detection Kit. 
Following overnight incubation CRL cells were detached using Trypsin EDTA and washed twice with cold 
Cell Staining Buffer. Cells were then resuspended in 100µl Annexin V binding buffer, transferred to FACS 
tubes and stained according to the package insert, summarized in Table 9. 
 
Table 9. Staining cells using FITC Annexin V kit. 
Cells Stain No. of samples 
Control: Untreated cells 
Unstained 2 
5 µl FITC Annexin + 10 µl PI 3 
Positive Control : 10µM 
Camptothecin 
5 µl FITC Annexin + 10 µl PI 3 
5 µl FITC Annexin 2 
10 µl PI 2 
10µg/ml Tat 5 µl FITC Annexin + 10 µl PI 3 
 
Cells were gently vortexed and incubated for 15mins in the dark, at room temperature. 
Flow cytometric data acquisition and analysis were conducted in a similar manner as to that described for 
the FITC Annexin V assay in the exogenous IL-6 and TNF-α  exposure. 
 
A1-A5 = Control: untreated cells only 
B1-B6, C1=  Positive control: 10µM 
Camptothecin  
D1-D3 =  Medium from 10µg/ml Tat exposed 
U87 cells 
Figure 16. A 24-well tissue culture plate seeded with CRL cell lines for FITC Annexin V analysis. 
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 
2.7.2 Phycoerithrin (PE) active caspase-3 assay 
U87 and CRL cells were grown to confluence and seeded onto 2 separate 24-well tissue culture plates (1 
x 106 cells per well with 500µl medium) (Figure 15 and 17). 2 hours prior to Tat or LPS exposure, medium 
from each well of U87 cells were discarded and 250µl serum free medium was added. 2 hours later, U87 
cells were treated as in Figure 16. Following a 4 hour incubation period the U87 cell medium was collected 
and centrifuged at 1500rpm for 5mins. CRL cell medium was discarded and U87 medium was added to 
the CRL cell lines (Figure 16). 10µM Camptothecin was used as a positive control for apoptosis (Figure 








2.7.2.1 Cell staining for caspase-3 detection 
Apoptosis induction by cytokines IL-6 and TNF-α  in  CRL  cell  lines  was  evaluated  using  the  PE  Active  
Caspase-3 apoptosis Kit. Following the overnight incubation period cells were detached using Trypsin and 
stained according to the manufacturer’s protocol. A summarized of the protocol is shown in Table 8. 
Flow cytometric data acquisition and analysis were conducted in a similar manner as to that described for 
the PE active caspase-3 assay in the exogenous IL-6 and TNF-α  exposure. 
 
 
A1-A5 = Control: untreated cells only 
B1-B3   =  Positive control: 10µM  
Camptothecin 
D1-D3 = 10µg/ml Tat 
Figure 17. A 24-well tissue culture plate seeded with CRL cell lines for caspase-3 analysis. 
   
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2.8 Statistical analyses 
All data generated was analyzed using GraphPad Prism 6 software. ANOVA followed by Bonferroni’s 
multiple comparison test was used to identify significant differences between groups. A p value of <0.05 
was considered significant.  Results are expressed as mean ± SEM as indicated.  
   
 
Figure 18. A and B showing CEM-GFP cells, containing a stably integrated GFP gene under the control of 
HIV-1 subtype- B LTR, the control groups included untreated CEM-GFP cells. Cells were grown in 24-well 
plates and incubated overnight. Images were captured using fluorescent microscopy (Zeiss Fluorescent 




3.1 Commercially procured HIV-1 Tat is biologically active 
3.1.1 Microscopic analysis 
HIV-1 B Tat protein viability testing was used to determine the viability of commercially procured Tat. 
The BioPORTER reagent assay was used to transfect CEM-GFP cell lines with Tat protein. CEM cells 
contain the GFP gene under the control of HIV-1 subtype-B long terminal repeat (LTR). Biologically active 
Tat binds to a trans-activating region within the LTR and this binding leads to the activation of the GFP 
gene. Cells that were exposed to Tat protein will therefore only fluoresce green if Tat is indeed biologically 
active. The following images were captured using fluorescent microscopy (Zeiss Fluorescent Microscope, 
LSM 880) at a 10X magnification. Figure 18 A and B, show the negative control group of untreated CEM-
GFP cells where no fluorescence was evidenced. Figure 19 A and B show the positive control group where 
the cells were exposed to 1ng/ml FITC Antibody. Here a large population of the cells fluoresced green. In 
Figure 20 A and B, the experimental group of cells transfected with 10µg/ml Tat protein, showed similar 












Figure 19. A and B showing CEM-GFP cells, containing a stably integrated GFP gene under the control of 
HIV-1 subtype- B LTR,  the positive control groups were exposed to FITC-Antibody. Cells were grown in 
24-well plates, exposed to 1ng/ml FITC-Antibody and incubated overnight. Images were captured using 
fluorescent microscopy (Zeiss Fluorescent Microscope, LSM 880) at a 10X magnification. 
Figure 20. A and B showing CEM-GFP cells, containing a stably integrated GFP gene under the control of 
HIV-1 subtype- B LTR, these groups were transfected with HIV-1 B Tat protein. Cells were grown in 24-
well plates, exposed to 10µg/ml Tat and incubated overnight. Images were captured using fluorescent 





















3.2 HIV-1 Tat stimulates astrocyte activation 
U87 cell lines were exposed to either 1µg/ml LPS or 10µg/ml HIV-1 B Tat, and the expression of glial 
fibrillary acidic protein (GFAP) was subsequently assessed as an indicator of astrocyte activation. Western 
blot analysis indicated higher expression levels of GFAP in LPS treated cells when compared to negative 
controls, while cells exposed to Tat protein had the highest expression levels (Figure 21 A). Band volumes 
and normalization calculations were generated via the ChemiDoc MP software. U87 cells exposed to LPS 
showed significantly greater expression levels than negative controls, with cells exposed to Tat protein 
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Figure 21. Western blot analysis of GFAP in U87 cell lines was used to determine whether HIV-1 B Tat protein 
causes astrocyte activation. The band intensities were normalized using stain-free technology and the 
ChemiDoc MP system. Precision Plus Protein Dual Xtra standard was used as the molecular marker. U87 cells 
were grown in 24-well plates and exposed to 10µg/ml HIV-1 B Tat or 1µg/ml LPS and western blot analysis 
was performed as described in section 2.4. GFAP protein can be seen at 50kDA and degraded GFAP at 45kDa. 
(B) GFAP band intensities (band volumes determined by ChemiDoc MP System) were expressed as mean ± 
SD of the experiment, p<0.05 were significantly different from other treatment groups, with *** being most 
significant and * being least significant (A vs C ns, A vs B ns and B vs C **). ANOVA followed by the 





Figure 22. Standard curve for TNF-α.  Curve  was  generated  using  Graph  Pad  Prism 6, with an R square 
value of 0.99. 
3.3 IL-6 and TNF-α  release  by  HIV-1 Tat exposed astrocytes                             
Enzyme-linked immunosorbent assays (ELISAs) were used to determine the release of IL-6 and TNF-α  
into the cell culture medium from Tat or LPS stimulated U87 cells. 
3.3.1 TNF- α  release 
U87 cells were exposed to LPS or Tat, incubated for 2 hours and processed according to the manufacturer’s 
instructions of the Human TNF-α  ELISA  Max Deluxe ELISA kit. Figure 22 represents the standard that 
was generated to determine the unknown values of TNF-α  release  per  experimental  condition.  There  was  
no significant difference in TNF-α   levels   in   the   culture   medium of U87 cells exposed to LPS when 
compared to controls (1.14 ± 0.44pg/ml vs 0.40 ± 0.44pg/ml). However the culture medium of cells 
exposed to Tat had a significantly higher concentration of TNF-α  when  compared  to  both  controls  and  LPS  
treated cells (2.52 ± 0.44pg/ml vs 0.40 ± 0.44pg/ml and 2.52 ± 0.44pg/ml vs 1.14 ± 0.44pg/ml) respectively 


























Figure 23. ELISA was used to determine the release of TNF-α  from  U87  cells  exposed  to  HIV-1 B Tat protein
or lipopolysaccharide (LPS). U87 cells were grown in 24-well plates and exposed to 10µg/ml Tat or 1µg/ml 
LPS. Following 1 hour of incubation, cell supernatant was collected and the ELISA assay was performed 
according to section 2.5.1. Results were expressed as mean ± SD of the experiment, p<0.05 were significantly 
different from other treatment groups, with *** being most significant and * being least significant (A vs C ns, 
A vs B ns and B vs C *). ANOVA followed by the Bonferroni`s multiple comparison test were done. All 











































Figure 24. Standard curve for IL-6. Curve was generated using Graph Pad Prism 6, with an R square 
value of 0.98. 
3.3.2 IL-6 release 
The same culture medium used to determine the levels of TNF-α  above,  was  used  to  measure  the  content  
of IL-6. Figure 24 is a representative standard curve of the assay which was used to determine the 
concentration of IL-6 in each sample. Similar to TNF-α,  there  was  no  significant difference in IL-6 levels 
in the culture medium of LPS exposed and control cells (Figure 25). However the culture medium of Tat 
treated cells had significantly higher IL-6 levels than both LPS and control cells (Figure 25). The levels of 
IL-6 per group were 11.68 ± 1.05pg/ml for the Tat (10µg/ml) stimulated cells, 5.72 ± 1.05pg/ml for the 





























Figure 25. ELISA was used to determine the release of IL-6 from U87 cells exposed to HIV-1 B Tat or
lipopolysaccharide (LPS). U87 cells were grown in 24-well plates and exposed to 10µg/ml Tat or 1µg/ml 
LPS. Untreated U87 cells served as the negative control. Following 1 hour of incubation, cell supernatant was 
collected and the ELISA assay was performed according to section 2.5.2. Results were expressed as mean ± 
SD of the experiment. A value of p<0.05 was significantly different from other treatment groups, with *** 
being most significant and * being least significant (A vs C ns, A vs B ns and B vs C *). ANOVA followed 
by the Bonferroni`s multiple comparison test were done. All statistical analysis was carried out using 




































Figure 26. Flow cytometric analysis illustrating the negative control population of untreated CRL cells. 
3.4 IL6 and TNF-α  induces  apoptosis  in  neurons 
To assess whether IL-6 and TNF-α  were  toxic  to  neuronal  cells,  we  exposed  CRL  cells  to  these  cytokines  
and determined the presence of apoptotic cell death. Annexin V and caspase-3 expression levels were 
measured by flow cytometry methods in order to gauge to the extent of apoptosis. 
3.4.1 Apoptosis detection using the FITC Annexin V assay 
CRL cell lines were exposed to commercially obtained recombinant TNF-α  (100ng/ml), IL-6 (100ng/ml) 
or a combination of TNF-α   and   IL-6. The cells were then incubated with Annexin V, a phospholipid 
binding protein conjugated to the FITC fluorochrome and subjected to flow cytometry. 10µM camptothecin 
was used as a positive control.  
Figures 26, 27, 28, 29 and 30 are representative flow cytometric scatter graphs of negative control cells 
(untreated CRL cells, Figure 26), the positive control (Figure 27) and the treated CRL cells (Figure 28: 
100ng/ml TNF-α;;  Figure  29:  100ng/ml  IL-6; Figure 30: TNF-α  +  IL-6). The negative control cells showed 
an apoptotic percentage of 8.1% (Figure 26), the positive control 38.2% (Figure 27), cells exposed to TNF-
α  27.7%  (Figure  28),  cells  exposed  to  IL-6 14.0% (Figure 29) and cells exposed to both TNF-α  and  IL-6 
14.8% (Figure 30). These percentages were the average of 3 experiments. All treated cells including the 
positive control showed significantly higher levels of Annexin V staining when compared to untreated 
CRL control cells (Figure 31), with camptothecin giving the highest level followed closely by TNF-α.  
Although IL-6 and the combination of TNF-α  and  IL-6 also yielded significantly high levels of apoptosis, 
these were not to the same level as TNF-α  (Figure  28). All tests were done in triplicate and each Figure 
represents one such test. 
 







Figure 27. Flow cytometric analysis illustrating the positive control (10µM camptothecin) population of CRL 
cells.  
Figure 28. Flow cytometric analysis illustrating CRL cells exposed to recombinant 100ng/ml TNF-α. 
Figure 29. Flow cytometric analysis illustrating CRL cells exposed to 100ng/ml recombinant IL-6. 
 


















Figure 30. Flow cytometric analysis illustrating CRL cells exposed to 100ng/ml recombinant TNF-α  and  IL-6. 
Figure 31.  Annexin V, a phospholipid binding protein conjugated to the Fluorescein isothiocyanate (FITC) 
fluorochrome, and flow cytometry was used to determine the apoptotic inducing effect of recombinant 
TNF-α  and  IL-6 on CRL cells.  Cells were grown in 24-well plates and exposed to 100ng/ml recombinant 
IL-6 or 100ng/ml of recombinant TNF-α,  or  a  combination of recombinant IL-6 and TNF-α.  The  positive  
control included CRL cells exposed to 10µM camptothecin and untreated CRL cells were used as the 
negative control. Cultures were incubated overnight and analyzed using the LSR Fortessa SORP flow 
cytometer. Results were expressed as mean ± SEM of 3 experiments. A value of p<0.05 was considered to 
indicate significant differences between treatment groups, with *** being most significant and * being least 
significant (A vs B ***, A vs C *, A vs D *, A vs E *, B vs C ***, B vs D ***, B vs E **, C vs D ns and 
C vs E ns). ANOVA followed by the Bonferroni`s multiple comparison tests were done on the data. All 































Effect of Recombinant TNF-α  and  IL-6  
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Figure 32. Flow cytometric analysis illustrating the negative control population of untreated CRL cells. 
3.4.2 Apoptosis detection using caspase-3 assay 
Similar to the Annexin V experiments, another batch of CRL cell lines were exposed to recombinant TNF-
α,  IL-6 or a combination of TNF- α  and  IL-6 in order to investigate the apoptotic effect of these cytokines 
on CRL cells using caspase-3 expression as indicator. An intracellular staining application using 
phycoerythrin (PE) rabbit anti-active caspase-3 antibody was used to determine caspase-3 expression on 
the flow cytometer. CRL cells were incubated with 100ng/ml TNF-α,  100ng/ml  IL-6, or a combination of 
100ng/ml TNF- α  and  100ng/ml  IL-6 and incubated overnight. A positive control of 10µM camptothecin 
was again used. Negative control (Figure 32) cells (untreated CRL cells) showed an average apoptotic 
percentage of 0.4%, positive control (10µM camptothecin) 17.1% (Figure 33), TNF-α  treated  cells  17%  
(Figure 34), IL-6 treated cells 8.1% (Figure 35) and, the combination of TNF-α  and  IL-6 treatments 10.9% 
(Figure 36). All tests were done in triplicate and each Figure represents one such test. 
Statistical analysis of the flow cytometry data showed that all treatments induced a significantly high 
expression of caspase-3 when compared to the untreated control cells (Figure 37). Camptothecin and TNF-
α  induced   the  highest   level  of   caspase-3 expression, with IL-6 and the combination of IL-6 and TNF-α  
resulting in caspase-3 levels that were nearly half the level of that of TNF-α  (Figure  37). 
 
  










Figure 33. Flow cytometric analysis illustrating the positive control population (10µM camptothecin) of 
CRL cells. 




















Figure 35. Flow cytometric analysis illustrating CRL cells exposed to 100ng/ml recombinant IL-6.  
Figure 36. Flow cytometric analysis illustrating CRL cell exposed to 100ng/ml recombinant TNF-α  and  IL-6. 








   










Figure 37. An intracellular staining application using phycoerythrin (PE) rabbit anti-active caspase-3 
antibody, and flow cytometry to determine the apoptotic inducing effect of recombinant TNF-α  and  IL-6 
on CRL cells. Cells were grown in 24 well plates and exposed to 100ng/ml recombinant IL-6 or  TNF-α,  or  
a combination of recombinant IL-6 and TNF-α.  The  positive  control  included  CRL  cells  exposed  to  10µM  
camptothecin and untreated CRL cells served as the negative control. Cultures were incubated overnight 
and analysis was done using the LSR Fortessa SORP flow cytometer. Results were expressed as mean ± 
SEM of the 3 experiments. A value of p<0.05 was significantly different from other treatment groups, with 
*** being most significant and * being least significant (A vs B ***, A vs C ***, A vs D *, A vs E *** B 
vs C *, B vs D * and B vs E *). ANOVA followed by the Bonferroni`s multiple comparison test were done. 
All statistical analysis was carried out using GraphPad Prism 6. 





































Figure 38. Flow cytometric analysis illustrating the negative control population of untreated CRL cells. 
3.5 The culture medium of HIV-1 Tat exposed astrocytes induce apoptosis in neurons  
The culture medium of astrocytes that were exposed to Tat were collected and added to the growth medium 
of the neuron culture. This was done to see if the culture medium of Tat-exposed astrocytes could induce 
apoptotic cell death of neurons. 
3.5.1 Apoptosis detection using the FITC Annexin V assay 
CRL cell lines were exposed to cell culture supernatant of U87 cells that were previously treated with HIV-
1 B Tat. Staining the CRL cells with Annexin V subsequently assessed evidence of apoptosis. U87 cells 
were incubated with Tat for 1 hour, after which the medium was collected, pooled and centrifuged. This 
medium was then added to CRL cells and incubated overnight. Negative control (untreated CRL cells) 
showed an average apoptotic percentage of 2.2% (Figure 38), positive control (10µm camptothecin 
exposed CRL cells) 36.2% (Figure 39), and the Tat treated astrocyte medium exposed CRL cells 9.4 % 
(Figure 40). All tests were done in triplicate and each Figure represents one such test. 
Statistical analysis showed that both camptothecin and the Tat treated astrocyte culture medium increased 
Annexin V staining significantly when compared to the negative control cells (Figure 41). The increase in 
Annexin V staining induced by camptothecin was substantially more than the Tat treated astrocyte medium 
(Figure 41).   
  
  








Figure 39. Flow cytometric analysis illustrating the positive control (10µm camptothecin) population of CRL 
cells. 
Figure 40. Flow cytometric analysis illustrating CRL cells exposed to the collected cell culture supernatant from 
U87 cells that were treated with 10µg/ml HIV-1 B Tat. 
  
 
   
  
















Figure 41. Annexin V, a phospholipid binding protein conjugated to the fluorescein isothiocyanate (FITC) 
fluorochrome was used to determine the apoptotic inducing effect in CRL cells exposed to the cell culture 
medium collected from U87 cells that were treated with 10µg/ml HIV-1 B Tat. Cells were grown in 24 
well plates and incubated overnight with either 10µm camptothecin (positive control) or the cell culture 
supernatant of U87 cells exposed to Tat. The negative control group was untreated CRL cells. The analysis 
was done using the LSR Fortessa SORP flow cytometer. Results were expressed as mean ± SEM of 3 
experiments. A value of p<0.05 was significantly different from other treatment groups, with *** being 
most significant and * being least significant (A vs B ***, A vs C ** and B vs C ***).  ANOVA followed 
by the Bonferroni`s multiple comparison test were done. All statistical analysis was carried out using 
GraphPad Prism 6. 
3.5.1.1 Statistical Analysis 
 































Figure 42. Flow cytometric analysis of the negative control population of untreated CRL cells. 
 
3.5.2 Apoptosis detection using the Active PE caspase-3 assay 
Similar to the Annexin V experiment, CRL cell lines were once again exposed to either camptothecin or 
Tat treated U87 cell supernatant to investigate the effect of this supernatant on the expression levels of 
caspase-3. The PE active Caspase-3 apoptosis kit was used to establish apoptotic cell death. 
Negative control (untreated CRL cells) (Figure 42) showed an average apoptotic percentage of 0.27%, 
positive control (10µm camptothecin) 54.9% (Figure 43), and the Tat treated U87 cell supernatant 1.6 % 
(Figure 44). All tests were done in triplicate and the Figure represents one such test. 
Statistical analysis of the data showed that although camptothecin induced a significant increase in caspase-
3 expression in CRL cells, exposure of these cells to the cell culture supernatant of U87 cells that were 














Figure 43. Flow cytometric analysis of the positive control (10µm camptothecin) population of CRL cells. 
Figure 44. Flow cytometric analysis of the CRL cells exposed to the cell culture supernatant of U87 cells that 
were previously exposed to 10µg/ml HIV-1 B Tat. 
 








   









Figure 45. An intracellular staining application using phycoerythrin (PE) rabbit anti-active caspase-3 
antibody, and flow cytometry to determine the apoptotic inducing effect in CRL cells exposed to the cell 
culture medium collected from U87 cells that were treated with 10µg/ml HIV-1 B Tat. Cells were grown in 
24 well plates and incubated overnight with either 10µm camptothecin (positive control) or the cell culture 
supernatant of U87 cells exposed to Tat. The negative control group was untreated CRL cells. The analysis 
was done using the LSR Fortessa SORP flow cytometer. Results were expressed as mean ± SEM of 3 
experiments. A value of p<0.05 was significantly different from other treatment groups, with *** being most 
significant and * being least significant (A vs B ***, A vs C ns and B vs C ***).  ANOVA followed by the 
Bonferroni`s multiple comparison test were done. All statistical analysis was carried out using GraphPad Prism 
6. 



































HIV is most well-known for its negative effects on the immune system and the resulting development of 
AIDS, however it also has severe damaging effects on the central nervous system (CNS) (Palacio et al., 
2012). Many infected individuals exhibit neuropsychological and behavioral dysfunctions which are 
collectively referred to as HIV-associated dementia (HAD) (Bhattacharya and Osman, 2009). One of the 
worrying aspects of HAD is the fact that current anti-retroviral therapy, while being effective in managing 
the onslaughts of HIV on the immune system, is less efficient in addressing the impact of HIV on the CNS. 
One of the reasons for this undesirable aspect of the management of HIV, is the lack of in-depth knowledge 
of the etiology of HAD and subsequently a shortage of targeted therapeutic approaches to deal with it 
effectively. 
A number of proposals have attempted to explain the development of HAD (Brabers and Nottet, 2006; 
Nielsen et al., 1984; Price et al., 1988) indicating both host and viral proteins as potential causative 
candidates (Kaul et al., 2001; Li et al., 2009; Rappaport et al., 1999; Shi et al., 1998). As such, Tat protein, 
one of the regulatory proteins of HIV, has been identified as a possible etiological factor of HAD (Price et 
al., 1988). Normal functions of Tat includes the augmentation of viral transcription, assisting in efficient 
replication and survival of the virus (Bagashev and Sawaya, 2013). However, Tat can be extremely harmful 
to host cells due to some of the exceptional abilities it possesses. For example, Tat can enter and exit cells 
with ease, travelling between cells, infecting uninfected bystander cells and disrupting essential pathways 
within cells (Bagashev and Sawaya, 2013). There are no effective treatment regimens that block Tat 
activity, and even in the presence of ARV’s, Tat is persistently being produced by infected cells (Li et al., 
2009). It is obvious that the mechanisms Tat implements to exert its effects are multifaceted and therefore 
require further investigation.  
Neurotoxicity caused by HIV-1 is an indirect effect since the virus is unable to infect neurons directly 
(Gendelman et al., 1994). In lieu of this we hypothesized that HIV infects non-neuronal cells in the CNS 
that leads to their activation, resulting in the release of cytokines that are detrimental to neurons. To test 
our hypothesis we exposed astrocytes to Tat and assessed whether this leads to the secretion of the pro-
inflammatory cytokines tumor necrosis factor-α   (TNF-α)   and   interleukin-6 (IL-6). We subsequently 





Is commercially procured HIV-1 Tat protein biologically active? 
In order for us to successfully perform the experiments, we had to assess whether the Tat that we procured 
from commercial sources was biologically active. The viability of our clade B Tat protein was determined 
by transfecting CEM-GFP cells with Tat protein. In these cells GFP is under the control of HIV-1 subtype-
B LTR, with the result that only biologically active Tat can drive the fluorescence of GFP in CEM-GFP 
cells. According to our obtained results, microscopic analysis of CEM-GFP cells exposed to Tat fluoresced 
green, demonstrating that commercially procured Tat protein used in this study was indeed biologically 
active. These observations were therefore similar to a previous study in our laboratory (Ramautar et al., 
2012) and in accordance with the findings of Siddappa et al. (2006). We were therefore confident that the 
Tat used in subsequent experiments would generate results that could give insights into the in vivo situation 
where individuals are infected with HIV. 
Does HIV-1 Tat stimulate astrocyte activation? 
After we have established the biological activity of Tat, we investigated the ability of this protein to 
stimulate astrocytes. We focused on glial fibrillary acidic protein (GFAP) not only because it is a known 
molecular marker specific for astrocytes, but also because it has been shown to label most, if not all, 
reactive astrocytes that are responding to CNS injuries and infection (Molofsky et al., 2012; Sofroniew and 
Vinters, 2010). Western blot analysis showed that astrocytes exposed to Tat yielded a significantly greater 
GFAP band intensity when compared to the band intensity of the control group of untreated astrocytes. 
This finding suggested that treating astrocytes with Tat results in their activation. Zhou et al. (2004) 
reported a similar observation previously.  
Astrocytes have various critical functions which pose a huge impact on the form and function of the CNS 
(Wang and Bordey, 2008). Astrocytes are of particular interest since they are non-productively infected 
(Brabers and Nottet, 2006). In these cells, viral structural protein translation is defective and, only 
regulatory proteins including Tat, are produced (Brabers and Nottet, 2006). One of the effects of Tat is the 
activation of uninfected astrocytes.  Activated astrocytes cause toxic effects such as cytokine production 
to intensify inflammation (Nath, 2002), production of neurotoxic levels of ROS, and many other toxic 
effects (Brambilla et al., 2005; Sofroniew and Vinters, 2010; Swanson et al., 2004). Studies have identified 
TNF-α   and   IL-6 to be among the cytokines released from activated astrocytes in response to certain 
bacterial and viral infections including HIV-1 (Lau and Yu, 2001). In view of these findings, we set out to 
determine whether astrocytes in our experiments were also releasing these two cytokines following 
exposure to Tat. Our interest in TNF-α  stems  from  reports  showing  TNF-α  to  be a major pro-inflammatory 
cytokine that plays a vital role in the pathogenesis of HIV-related cognitive abnormalities and other 
neurodegenerative disorders (Saha and Pahan, 2003). IL-6 on the other hand, has been shown to possess 
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pro-inflammatory, anti-inflammatory, neuroprotective and neurotoxic effects. Its function with respect to 
HIV infection however, remains unclear (Guzmán et al., 2010; Rincon, 2012; Scheller et al., 2011). 
Do activated astrocytes release IL-6 and TNF-α? 
The concentration of TNF-α  and  IL-6 were measured in the culture medium in which astrocytes treated 
with Tat were grown. ELISA assays showed that the culture medium of astrocytes exposed to Tat had 
significantly higher levels of TNF-α  and  IL-6 than non-treated controls. Interestingly, the level of TNF-α  
released from activated astrocytes was not as pronounced as that of IL-6. Tat treated cells released more 
than double the amount of IL-6 than the control group of untreated astrocytes. Our data therefore showed 
that IL-6 was over-expressed in cells that were exposed to Tat. This finding was not unexpected as 
astrocytes are known to be a major source of IL-6 in the CNS (Van Wagoner et al., 1999). Previous studies 
using a 10-fold higher concentration of Tat protein, and being administered at varying time intervals, 
obtained levels of TNF-α  and  IL-6 much higher than in our experiments (Chen et al., 1997; Nath et al., 
1999). The concentration of Tat used in our study was the minimum concentration which has been shown 
to elicit neurotoxic effects (Ramautar et al., 2012; Siddappa et al., 2006). Despite these discrepancies, our 
data was in alignment with the findings of others who demonstrated Tat to cause significant upregulation 
in the release of the pro-inflammatory cytokines, TNF-α  and  IL-6 from astrocytes (Gandhi et al., 2009). 
The release of these cytokines therefore appears to be a robust response of astrocytes following their 
exposure to Tat.  
Are IL-6 and TNF-α  toxic  to  neurons? 
Under physiological conditions TNF-α   and   IL-6 have pleiotropic and overlapping functions and are 
important in the induction and regulation of the immune response following infection (Arai et al., 1990; 
Lau and Yu, 2001). In order to determine the effects of these cytokines on neurons, we initially exposed 
our neuronal cells to exogenous recombinant IL-6 and TNF-α,   and   followed   this   experiment   with   the  
exposure of our neurons to the culture medium of astrocytes treated with Tat. Flow cytometry (Annexin V 
and caspase-3 staining) was used to determine the apoptotic inducing effect of these cytokines individually 
and in combination.  
Compared to the control group the TNF-α  and  IL-6 treated neuronal cells showed a significant percentage 
of apoptosis. Interestingly, the combination of TNF-α  and  IL-6 did not show an additive effect, but rather 
the apoptotic percentage of this combination was lower than that of TNF-α  alone.  There  was  therefore  no  
synergistic effect. Similar results were seen for both Annexin V and caspase-3 assays, thereby providing 
confidence in our results that indicated the level of apoptosis.  
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TNF-α  showed  a  greater  potency  to  induce  apoptosis  than  IL-6. The ability of TNF-α  to  induce  apoptosis  
is supported by evidence showing involvement of this cytokine and its receptors in the pathogenesis of 
HIV-related cognitive abnormalities and other neurodegenerative disorders (Saha and Pahan, 2003). For 
instance, studies have shown TNF-α   to   elicit   toxic  autocrine   and  paracrine   effects  on   cells  of   the  CNS  
(Hanisch, 2002; Sheng et al., 2005), that include the induction of neuronal apoptosis via the binding to its 
receptor and the subsequent activation of death signaling pathways (Muppidi et al., 2004; Sheng et al., 
2005; Wajant et al., 2003). 
The exact role of IL-6 in inflammation is controversial. For example, it has been shown to have beneficial 
effects because of its neurotrophic properties, however over-expression has been shown to be detrimental 
to the CNS (Van Wagoner et al., 1999). The decreased potency of the combined cytokine effect may be a 
result of IL-6 and its neuroprotective, anti-inflammatory effects that acted against the pro-inflammatory 
effects of TNF-α.   This   explanation   is   plausible   since   researchers   have   demonstrated   that   IL-6 offer 
protection against neurotoxicity, as well as having anti-inflammatory properties (Guzmán et al., 2010; 
Rincon, 2012; Scheller et al., 2011). However, others have reported that increased levels of IL-6 in the 
CNS have been demonstrated in several neurological diseases and in HIV infection (Qiu et al., 1998). 
These authors showed that IL-6 can be detrimental to the functioning of the CNS. The overall effect of IL-
6 therefore seems to be ambiguous, thereby requiring further investigation. 
Is the culture medium of HIV-1 Tat exposed astrocytes toxic to neurons? 
Since exogenous recombinant TNF-α  and  IL-6 caused a significant percentage of apoptosis of neuronal 
cells, the culture medium of astrocytes exposed to Tat was collected and added to the growth medium of 
the neuron culture. This was done to determine whether the culture medium of Tat-exposed astrocytes 
could induce IL-6 and TNF-αdirected   apoptotic   cell   death   of   neurons.   The   Annexin assay showed a 
significant percentage of apoptotic cell death of neurons exposed to Tat-treated astrocyte culture medium, 
compared to the control group. In contrast, the caspase-3 assay showed no such significance. These results 
led us to believe that although the apoptotic pathway was initiated, as supported by the Annexin assay data, 
the final executioning part of the pathway was not active, as reflected by the caspase-3 assay.  
As mentioned above IL-6 may have offered, to some extent, neuroprotective effects toward the neurons 
exposed to the insult of TNF-α,   thus   inhibiting   caspase-3 activation and downstream execution of 
apoptosis. This can be due to the possibility of TNF-α  and  IL-6 meeting at the same execution point which 
is caspase-3 activation, therefore dampening a synergistic effect. Alternatively, it may also be possible that 
the triggers of caspase-3 activation have been inadequate to elicit a strong enough signal that would drive 
the pathway to completion. The concentration of the recombinant TNF-α  and  IL-6 used to evaluate the 
effects of exogenous cytokines on neurons, were in the nanogram range, while the levels of these cytokines 
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measured in the culture medium of Tat-exposed astrocytes, were only in the picogram range. Previous 
studies show that cell death occurred at TNF-α  levels  between  5  and  20ng/ml  (Deghmane et al., 2009; 
Sheng et al., 2005). It is therefore possible that the lower levels of cytokines were unable to stimulate the 
entire apoptotic pathway to a sufficient extent that may lead to programmed cell death. In order for cells to 
undergo apoptosis, both the initiation and execution parts of the apoptotic pathway need to be activated 
(Riedl and Salvesen, 2007). The initiation part of the pathway can be activated by both the intrinsic or 
extrinsic pathway, and ends with the activation of caspase-9 and caspase-8 respectively. These caspases 
subsequently activate caspases-3 and 7, marking the beginning of the execution part that eventually results 
in apoptotic cell death. Recently there has been reports that caspase-8 may function as a switch between 
autophagy and apoptosis (Wu et al., 2014). Autophagy refers to the process whereby damaged intracellular 
proteins and organelles are hydrolyzed by lysosomial proteases for re-use by the cell. The autophagic 
process is therefore part of the cell’s attempts to survive under conditions of stress. It is likely that in our 
experiments a similar switching took place where apoptosis was initiated but not executed through the 


















There has been much progress in the management of HIV-1, leading to a significant increase in the life 
span of the HIV-infected individual. Despite the advances, some serious issues remain unresolved. For 
instance, to date current therapeutic approaches are still unable to eradicate the virus completely. The 
existence of residual reservoirs continues to be one of the major challenges facing scientists and clinicians 
working in this field of infectious diseases.  
Another area of concern revolves around the effects of HIV on the central nervous system. While 
antiretroviral therapy has been promising in extending an infected individuals’ life span by slowing down 
the rate of viral replication, the treatment of HIV-induced neurotoxicity appears to be problematic. One of 
the reasons for this inadequacy stems from the limited understanding of how the virus interacts with host 
cells, and in this case, cells of the nervous system. Our study focused on the engagement of HIV with 
astrocytes, and investigated how this interaction may lead to neuronal cell death. This study therefore 
attempted to provide a molecular basis that may explain the neuronal death seen in individuals diagnosed 
with HIV-associated dementia (HAD).  
We hypothesized that HIV infects astrocytes which results in the release of pro-inflammatory cytokines 
that are toxic to neurons. To prove our hypothesis we exposed astrocytes to the viral protein Tat and 
assessed whether such exposure would stimulate the secretion of TNF-α  and   IL-6 into the cell culture 
medium. We then subjected this culture medium to neurons and determined the level of apoptotic cell 
death. 
Our data showed that HIV-1 Tat protein exposure resulted in astrocyte activation and consequently the 
release of cytokines IL-6 and TNF-α  into  the  culture  medium. Interestingly, these cytokines individually, 
by exogenous administration, resulted in a significant amount of neuron death. However, in combination, 
they did not show an additive synergistic effect. This finding suggested that the two cytokines very likely 
utilize a common pathway to induce apoptotic cell death. Further exposure of neurons to these cytokines 
in the astrocyte-grown culture medium did not yield the same extent of neuronal apoptosis. Huge 
differences between the concentrations of exogenous cytokines and that present in the culture medium, can 
possibly explain this discrepancy.  Because of the rather low levels of cytokines, exposure of neurons to 
the culture medium resulted only in the initiation of neuronal apoptosis and not its final execution. A 
possible explanation for this observation may be that under conditions of exposure to low levels of pro-
inflammatory cytokines, cells have the opportunity to resort to autophagy as a survival mechanism, thus 
escaping the final stages of apoptotic induced cell death. This finding suggested that the concentration of 
pro-inflammatory cytokines might be important in determining the eventual fate of cells. 
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In summary our results suggest that HIV may activate astrocytes via Tat protein leading to the secretion of 
cytokines that may be toxic to neurons and cause their demise. These findings are helpful as it indicates 
that in addition to the use of existing antiretroviral therapy that mainly aims to reduce viral entry and 
replication, drugs that target inflammatory processes should also be considered in the management of 





















Our study generated a number of new ideas for future research. It would be useful to determine whether 
viral proteins other than Tat, produce similar effects, as we know that Tat is not the only protein secreted 
by HIV. Also it would be interesting to increase the time to which astrocytes are exposed to low levels of 
Tat. Such an approach may help us understand the impact of the residual reservoir of HIV on brain function. 
Since the results obtained in the present study were confined to in vitro studies, it would be ideal to repeat 
the experiments using an in vivo model. This may be important to confirm the in vitro generated data. 
Finally, it would be interesting to see whether an intervention aimed at reducing pro-inflammatory 
cytokines such as TNF-α  and  IL-6, would be able to decrease the level of apoptotic neuronal cell death, 
thereby providing a lead in the development of therapeutic strategies to combat Tat induced neurotoxicity 
and HAD. Since we did not measure the Tat concentration in the medium of Tat-exposed astrocytes, this 
medium collected and used for subsequent experiments could have contained residual Tat protein that may 
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HIV-1 Tat Protein 
Full length 86 amino acid HIV-1 Tat (clade B, 100µg) was resuspended in 200µl PBS: 
C1 V1 = C2 V2  
C2   = C1 x V1 / V2 
=100µg X 1ml = C2 X 0.2ml 
= 500µg/ml 
Therefore resuspending Tat in 200ul PBS gave a concentration of 500µg/ml.  
C1 (Tat total = 500µg/ml)  
V1 (?)  
C2 (Tat treatment = 10µg/ml)  
V2 (Medium in each treated well = 0.5ml) 
V1   = C2 x V2 / C1 
= 10µg/ml x 0.5ml / 500µg/ml 
= 0.01ml 
= 10µl 








Phosphate Saline Buffer (PBS) 
4 PBS tablets were dissolved in 1L distilled water. PBS solution was autoclaved in a Steridium 
Microdigital Autoclave (Steridium, Queensland, Australia) at 121kPa for 10mins, cooled and aliquoted in 
50ml aliquots prior to use. 
Appendix 3 
Lipopolysaccharide (LPS) 
5mg/ml solution of LPS was prepared as per package insert by the addition of 1ml endotoxin free water 
(included in package) to 5mg LPS. The recommended working concentration of LPS is 1ng/ml - 
10µg/ml. A 1µg/ml concentration was used. From the 5mg/ml solution, 0.01ml was removed and added 
to 990µl PBS to make up a stock solution of 0.05mg/ml. 
C1 (LPS stock = 0.05mg/ml = 50µg/ml)  
V1 (?)  
C2 (LPS treatment = 1µg/ml)  
V2 (Medium in each treated well = 0.5ml) 
V1    = C2 X V2 / C1 
= 1µg/ml x 0.5ml / (50µg/ml) 
= 0.01ml 
= 10µl 
The volume from the 0.05mg/ml stock solution that gave a final concentration of 1µg/ml when added to 
0.5ml medium was 10µl. 
 
 




1X Tris-Glycine - sodium dodecyl sulphate (TGS) 
100ml 10X TGS was added to 900ml distilled water resulting in a 1X TGS solution. 
Appendix 5 
1X Tris-Glycine buffer (TG) 
100 ml 10X TG was added to 900ml distilled water resulting in a 1X TG solution. 
Appendix 6  
1X Tris-Buffered Saline (TBS) 
100ml 10X TG was added to 900ml distilled water resulting in a 1X TG solution to which 1ml 0.01% 
Tween20 (Sigma, Missouri, US) was added. 
Appendix 7 
5% Bovine Serum Albumin (BSA) 
5g BSA was added to 100ml 1X TBS (Appendix 6), mix well. 
Appendix 8 
Primary Antibody 
Anti-GFAP Antibody (Rabbit-polyclonal to GFAP) was diluted according to the ratio 1:714, after various 
rounds of optimization. 21µl antibody was diluted in 15ml 5% BSA 
Appendix 9 
Secondary Antibody 
After various rounds of optimization the suitable dilution of Secondary Antibody (Anti-Rabbit) was 





1X Coating Buffer 
All reagents from Appendix 10 – 17 were included in the ELISA max deluxe kits. The preparation in the 
above-mentioned appendices was done separately for the IL-6 and TNF-α  experiments.  All  dilutions  
were done for one 96 MicroWell plate. 
2.4ml 5X Coating Buffer was added to 9.6ml de-ionized water. 
Appendix 11 
1:200 Capture Antibody 
60µl Capture Antibody was added to 11.94ml 1X coating buffer. 
Appendix 12 
Wash Buffer 
0.05% Tween 20 (0.5ml) was added to 1L PBS. 
Appendix 13 
1X Assay Diluent 
10 ml 5X assay diluent was added to 40ml PBS. 
Appendix 14 
Standard and Sample Dilution 
Standard Dilutions 
Standard was prepared and diluted as per package insert, where six 2 fold serial dilutions were made 
(500, 250, 125, 62.5, 31.3, 15.6, 7.8 pg/ml) using 1X Assay Diluent. 
Sample Dilutions 
Six 2 fold dilutions were prepared with the samples similar to the standard preparation. 100µl 1X Assay 









       200µl sample   
         Dilution                    1:2       1:4       1:8       1:16                   1:32 
Appendix 15 
1:200 Detection Antibody 
60µl Detection Antibody was added to 11.94ml 1X Coating Buffer. 
Appendix 16 
1:1000 Avidin-HRP 
6µl Avidin-HRP was added to 11.88ml 1X Assay Diluent 
Appendix 17 
TMB Substrate Solution 
6ml Substrate Solution A was added to 6ml Substrate Solution B 
Appendix 18 
10µM Camptothecin 
1mM stock solution of Camptothecin was prepared: 






N (moles)   = m (mass) /m (molar mass) 
= 0.0009g / 348.4g/mol 
= 0.000002583mol 
 
C (concentration) = n (moles) / v (volume) 
= 0.000002583mol / 0.001L 
= 0.002583mol/l 
= 2.583mM 
C1 (2583µm)  
V1 (?) 
C2 (100µm)  
V2 (1ml) 
 
V1    = C2 X V2 /C1 
=1mM x 1ml / 2.583mM 
= 0.387ml 
= 387µl 
This means that from the initial 1ml solution of Camptothecin, 387µl was removed and added to a new 
tube containing 913µl DMSO, which formed the 1mM stock solution. 
C1 (100µm)  
V1 (?)  
C2 (5µm)  
V2 (0.5ml) 
C1V1 = C2V2 
C1V1 = C2V2 
   
 
V1    = C2 X V2 /C1 
= 10µm x 0.5ml / 1000µm 
= 0.005ml 
= 5µl 
The volume from stock that gave a final concentration of 10µM Camptothecin was 5µl.  
Appendix 19 
1 X BD Perm/Wash 
If 8 tests were carried out, 13ml of 1 X BD Perm/Wash was needed therefore: 
1.3ml 10X BD Perm/Wash was added to 8.7ml distilled water. 
Appendix 20 
10% Ammonium persulphate 
0.1g APS was added to 1 ml distilled H20 
 
Appendix 21  
Recombinant TNF-α  and  IL-6 
Recombinant TNF-α 
10µg lyophilized TNF-α  was  purchased  and  the  reconstitution  concentration  was  0.1-1mg/ml. TNF-α  
was reconstituted in100µl distilled water giving a 0.1mg/ml concentration: 
10µg (0.01mg) in 1000µl and 0.1mg/ml in X 
X   = 0.01mg x 1000µl / 0.1mg/ml 
X   = 100µl 




C1 (Stock 0.1mg/ml)  
V1 (?)  
C2 (Treatment 100ng/ml = 0.0001mg/ml)  
V2 (Medium per well 0.5ml)  
 
V1 = C2V2 /C1 =   0.0001mg/ml x 0.5ml / 0.1mg/ml 
=   0.0005ml 
=   0.5µl 
The volume from the stock that gave a 100ng/ml concentration of TNF-α  was  0.5µl. 
 
Recombinant IL-6 
20µg lyophilized IL-6 was purchased and the reconstitution concentration was 0.1-0.5mg/ml. IL-6 was 
reconstituted in 200µl distilled water giving a 0.1mg/ml concentration: 
20µg (0.02mg) in 1000µl and 0.1mg/ml in X 
X   = 0.02mg x 1000µl / 0.1mg/ml 
X  = 200µl 
From the 200µl solution of 0.1mg/ml, 100ng/ml in a specific volume was required: 
C1 (Stock 0.1mg/ml)  
V1 (?)  
C2 (Treatment 100ng/ml = 0.0001mg/ml)  
V2 (Medium per well 0.5ml) 
 
 
C1V1 = C2V2 
C1V1 = C2V2 
   
 
V1 = C2V2 / C1 =   0.0001mg/ml x 0.5ml / 0.1mg/ml 
=   0.0005ml 
=   0.5µl 
The volume from the stock that gave a 100ng/ml concentration of IL-6 was 0.5µl. 
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